

Curriculum vitae of Rena M. Conti, Ph.D.

Associate Professor, Markets, Public Policy, and Law
Questrom School of Business
Co-director, Technology and Policy Research Institute
Boston University
Rafik B. Hariri Building
Office: 514b
595 Commonwealth Avenue
Boston, MA 02215

A.1. Academic appointments

- The University of Chicago
 - Instructor, Department of Pediatrics, Section of Pediatric Hematology and Oncology, 2006–2010.
 - Assistant Professor, Department of Pediatrics. Section of Pediatric Hematology and Oncology, 2010–2016.
 - Assistant Professor, Department of Public Health Sciences, 2013–2016.
 - Assistant Professor, Biological Sciences Collegiate Division, 2014–2016.
 - Associate Professor, Department of Pediatrics, Section of Pediatric Hematology and Oncology and Biological Sciences Collegiate Division, July 2016–July 2018.
 - Associate Professor, Harris School of Public Policy, January 2017–June 2018.
- Boston University
 - Associate Professor, Markets, Public Policy, and Law, Questrom School of Business, July 2018–present.
 - Associate Research Director, Biopharma and Public Policy, Institute for Health System Innovation and Policy, July 2018–December 2021.
 - Co-director, Technology and Policy Research Institute, July 2021-present.

A.2. Education

- Kenyon College, BA, Philosophy (high honors)
- Harvard University, PhD, Interfaculty Initiative in Health Policy; Concentration: Economics, Dissertation title: ‘The Economic Value of Antidepressant Prescription Drugs’

A.3. Previous employment

- Research Manager, Harvard School of Public Health, 1998-2000.
- Research Assistant, Department of Health Care Policy, Harvard Medical School, 2000-2006.

A.4. Invited, elected, or appointed extramural service

- NCORP, Alliance/Cancer and Leukemia Group B, Committee on Cancer Control and Health Outcomes, 2006–present.
- Ad hoc advisor, Finance Committee, HELP Committee of the US Senate, 2011–present. Consulted on prescription drug market and Coronavirus matters.
- Ad hoc advisor, US House of Representatives, 2011–present. Consulted on prescription drug market and Coronavirus matters.
- Clinical Trial Design Task Force, Investigation Drug Steering Committee, VOI Working Group, Co-chair, National Institutes of Health (NIH)/National Cancer Institute (NCI), 2012–2014.
- Government Relations Committee, American Society for Clinical Oncology, 2013–2016.
- Advisor (ad hoc), 60 Minutes, CBS News, 2014.
- Chair, Pre-conference on the Economics of Cancer Treatment, American Society for Clinical Oncology, 2014–June 2018.
- Advisor (ad hoc), Public Interest Division, Illinois Attorney General, 2014-present.
- Consultant, Center for Health Policy and Outcomes, Department of Epidemiology & Biostatistics, Memorial Sloan-Kettering Cancer Center, 2014–2018.
- Member (elected), PDQ Board on Financial Toxicity, NIH/NCI, 2015–present.
- Member (elected), Conference on Research in Income and Wealth, 2016–present.
- Advisory board member (appointed), CEPAC, Institute for Clinical and Economic Review, 2016–present.
- Ad hoc advisor, Department of Public Health, State of Louisiana, 2016–present. Consulted on prescription drug market and Coronavirus matters.

- Ad hoc advisor, National Governors Association, 2016–present. Consulted on prescription drug and Coronavirus matters.
- Advisory committee member (appointed), State Alternative Approaches to Financing for Effective Drug Reimbursement & Utilization Group (SMART-D Initiative), 2016-2020.
- Member (elected, ad hoc), National Academy of Sciences, Engineering, and Medicine Committee “Ensuring Patient Access to Affordable Drug Therapies,” 2016–2018.
- Special government advisor, Department of Health and Human Services, US Food and Drug Administration, Office of Generic Drugs, CDER, 2018-2021. Consulted on prescription drug market and Coronavirus matters.
- Special government advisor, Department of Health and Human Services, Centers for Medicare and Medicaid Services, 2022-present. Consulted on prescription drug market and Coronavirus matters.
- Prescription drug track lead, American Society of Health Economists, 2022-present.
- Manuscript reviewer for *American Economics Review*, *American Journal of Health Economics*, *American Journal of Public Health*, *British Medical Journal*, *Cancer*, *Journal of the American Medical Association*, *Journal of Clinical Oncology*, *Journal of General Internal Medicine*, *Journal of Health Economics*, *Journal of Mental Health Economics and Policy*, *Journal of the National Cancer Institute*, *Journal of Political Economy*, *Health Affairs*, *Health Economics*, *Health Services Research*, *Lancet*, *Medical Care*, *Nature*, *New England Journal of Medicine*, *Science*.

A.5. Testimony

A.5.a. Government testimony (selected, not comprehensive)

- “An Economic Assessment of the Causes and Policy Implications of Current Specialty Drug Shortages,” Senate Finance Committee, Drug Shortages: What Causes Them and What Can We Do about Them? Washington, DC, December. 2011.
- “An Economic Assessment of the Potential Paradoxical Effects of the 340B Program on the Financing and Organization of Medical Care,” Invited written statement, US House of Representatives, Energy and Commerce Committee hearing on “Examining the 340B Drug Pricing Program,” March 2015.

- “Who Makes This Drug? The Public Costs of Keeping the Identity of Contract Manufacturers of Biopharmaceuticals Secret,” Public Hearing and Federal Register submission on the Reauthorization of the Prescription Drug User Fee Act, US Food and Drug Administration, White Oak, MD, July 2015.
- “Determinants of Generic Drug Supply and Price,” Generic Drug User Fee Amendments of 2012 (GDUFA) Reauthorization, FY 2016 Regulatory Science Initiatives Part 15 Public Meeting, Public Hearing on the Reauthorization of the Prescription Drug User Fee Act, US Food and Drug Administration, White Oak, MD, May 2016.
- “High Prescription Drug Prices: Causes, Consequences, Reform Opportunities,” Oral testimony and written prepared statement in front of the City of Chicago, Committee on Finance, Public hearing on “Chicago Drug Pricing Transparency Ordinance.” August 2017.
- “Challenges in Maintaining Competition in Small Generic Drug Markets II,” FDA Public Meeting, Ensuring Competition in Generic Drug Markets, Silver Spring, MD, October 2017.
- “High Prescription Drug Prices: Balancing Access and Affordability,” Federal Trade Commission workshop on “Understanding Competition in Prescription Drug Markets: Entry and Supply Chain Dynamics,” Washington, DC, November 2017.
- “Unsustainable Drug Prices: Findings from the Committee’s Drug Pricing Investigation and the Need for Structural Reforms,” U.S. House of Representatives, House Oversight Committee, December 2021.
- “Prescription Drug Spending Reform Will Not Harm Innovation and Will Benefit the American Public,” U.S. Senate, Senate Finance Committee, March 2022.

A.6. Publications

A.6.a. Peer-reviewed publications in the primary literature, exclusive of abstracts

- Epstein, AM, JZ Ayanian, JH Keogh, SJ Noonan, N Armistead, PD Cleary, JS Weissman, JA David-Kasdan, D Carlson, J Fuller, D Marsh, and RM Conti. “Racial Disparities in Access to Renal Transplantation—Clinically Appropriate or Due to

- Underuse or Overuse?" *New England Journal of Medicine*. 343, no. 21 (2000): 1537–44.
- Frank, RG, RM Conti, and HH Goldman. "Mental Health Policy and Psychotropic Drugs." *Milbank Quarterly*. 83, no. 2 (2005): 271–98.
 - Rosenthal, MB, MB Landrum, E Meara, HA Huskamp, RM Conti, and NL Keating. "Using Performance Data to Identify Preferred Hospitals." *Health Services Research*. 42, no. 6 Pt 1 (2007): 2109–19; discussion 2294–323.
 - Chien, AT, RM Conti, and HA Pollack. "A Pediatric-Focused Review of the Performance Incentive Literature." *Current Opinion in Pediatrics*. 19, no. 6 (2007): 719–25.
 - Conti, RM, DO Meltzer, and M Ratain. "Nonprofit Biomedical Companies." *Clinical Pharmacology and Therapeutics*. 84, no. 2 (2008): 194–97.
 - Qato, DM, GC Alexander, RM Conti, M Johnson, P Schumm, and ST Lindau. "Use of Prescription and Over-the-Counter Medications and Dietary Supplements among Older Adults in the United States." *Journal of the American Medical Association*. 300, no. 24 (2008): 2867–78.
 - Conti, RM, DL Veenstra, K Armstrong, LJ Lesko, and SD Grosse. "Personalized Medicine and Genomics: Challenges and Opportunities in Assessing Effectiveness, Cost-Effectiveness, and Future Research Priorities." *Medical Decision Making*. 30, no. 3 (2010): 328–40. Epub 2010 Jan. 4.
 - Meltzer, DO, A Basu, and RM Conti. "The Economics of Comparative Effectiveness Studies: Societal and Private Perspectives and Their Implications for Prioritizing Public Investments in Comparative Effectiveness Research." *Pharmacoeconomics*. 28, no. 10 (2010): 843–53.
 - Conti, RM, AB Busch, and DM Cutler. "Overuse of Antidepressants in a Nationally Representative Adult Patient Population in 2005." *Psychiatric Services*. 62 (2011): 720–26.
 - Dorsey, ER, A Rabbani, SA Gallagher, RM Conti, and GC Alexander. "Impact of FDA Black Box Advisory on Antipsychotic Medication Use." *Archives of Internal Medicine*. 170, no. 1 (2011): 96–103.

- Qato, DM, ST Lindau, RM Conti, LP Schumm, and GC Alexander. “Racial and Ethnic Disparities in Cardiovascular Medication Use among Older Adults in the United States.” *Pharmacoepidemiology and Drug Safety*. 19, no. 8 (2010): 834–42.
- Dorsey, ER, SA Gallagher, GC Alexander, and RM Conti. “Trends in the Use of Atypical Antipsychotics for the Treatment of Bipolar Disorder in the United States, 1998–2009.” *Psychiatric Services*. 63 (2011): 230–36.
- Philipson, TJ, M Eber, DN Lakdawalla, M Corral, RM Conti, and DP Goldman. “An Analysis of Whether Higher Health Care Spending in the United States Versus Europe Is ‘Worth It’ in the Case of Cancer.” *Health Affairs (Millwood)*. 31 (2012): 667–75.
- Conti, RM, MB Rosenthal, B Polite, PB Bach, and Y-C T Shih. “Infused Chemotherapy Use Following Patent Expiration among Individuals Aged 65 and Older.” *American Journal of Managed Care*. 18, no. 2 (2012): e173–78.
- Dusetzina, SB, AS Higashi, ER Dorsey, RM Conti, HA Huskamp, S Zhu, CF Garfield, and GC Alexander. “Impact of FDA Drug Risk Communications on Health Care Utilization and Health Behaviors: A Systematic Review.” *Medical Care*. 50, no. 6 (2012): 466–78.
- Dusetzina, SB, AB Busch, RM Conti, JM Donohue, GC Alexander, and HA Huskamp. “Changes in Antipsychotic Use among Patients with Severe Mental Illness after a Food and Drug Administration Advisory.” *Pharmacoepidemiology and Drug Safety*. 21, no. 12 (2012): 1251–60. Epub May 3, 2012.
- Kornfield, R, S Watson, AS Higashi, RM Conti, SB Dusetzina, CF Garfield, ER Dorsey, HA Huskamp, and GC Alexander. “Effects of FDA Advisories on the Pharmacologic Treatment of ADHD, 2004–2008.” *Psychiatric Services*. 64, no. 4 (2013): 339–46.
- Conti, RM. “Eliminate Cost-Plus Reimbursement for Drugs.” *Clinical Advances in Hematology & Oncology*. 12, no. 1 (2014): 66. PubMed PMID: 25129910.
- Conti, RM, AC Bernstein, VM Villaflor, RL Schilsky, MB Rosenthal, and PB Bach. “Prevalence of Off-Label Use and Spending in 2010 among Patent-Protected Chemotherapies in a Population-Based Cohort of Medical Oncologists.” *Journal of*

- Clinical Oncology/American Journal of Managed Care*. 31, no. 9 (2013): 1134–39. Epub 2013 Feb. 19.
- Conti, RM, SB Dusetzina, AC Herbert, ER Berndt, HA Huskamp, and NL Keating. “The Impact of Emerging Safety and Effectiveness Evidence on the Use of Physician-Administered Drugs: The Case of Bevacizumab for Breast Cancer.” *Medical Care*. 51, no. 7 (2013): 622–27.
 - Conti, RM, and PB Bach. “Cost Consequences of the 340B Drug Discount Program.” *Journal of the American Medical Association*. 309, no. 19 (2013): 1995–96.
 - Goldberg, P, and RM Conti. “Problems with Public Reporting of Cancer Quality Outcomes Data.” *Journal of Oncology Practice*. 10, no. 3 (2014): 215–18.
 - Gibbons, RD, M Coca-Perraillon, K Hur, RM Conti, RJ Valuck, and DA Brent. “Antidepressant Treatment and Suicide Attempts and Self-Inflicted Injury in Children and Adolescents.” *Pharmacoepidemiology and Drug Safety*. 24, no. 2 (2014): 208–14. Epub Sept. 29, 2014.
 - Conti, RM, A Fein, and S Bhatta. “National Trends in Spending on and Use of Oral Oncologics, 2006–2011.” *Health Affairs (Millwood)*. 33, no. 10 (2014): 1721–27.
 - Conti, RM, and PB Bach. “The 340B Drug Discount Program: Hospitals Generate Profits by Expanding to Reach More Affluent Communities.” *Health Affairs (Millwood)*. 33, no. 10 (2014): 1786–92.
 - Clark, B, J Hou, E Huang, C Chou, and RM Conti. “The 340B Drug Discount Program: Outpatient Prescription Dispensing Patterns through Contract Pharmacies in 2012.” *Health Affairs (Millwood)*. 33 (2014): 2012–17.
 - Conti, RM, and PB Bach. “Improving Outpatient Oncology Practice: Several Steps into a Long Journey.” *Journal of Oncology Practice*. 10, no. 6 (2014): 355–56. Epub 2014 Oct. 14, 2014.
 - Polite, BN, JC Ward, JV Cox, RF Morton, J Hennessy, RD Page, R, and M Conti. “Health Policy. Payment for Oncolytics in the United States: A History of Buy and Bill and Proposals for Reform.” *Journal of Oncology Practice*. 10, no. 6 (2014): 357–66.

- Conti, RM. “Expanding the Scope of the National Practice Oncology Benchmark Would Be a Critical Source for Understanding Outpatient Oncology Practice Costs and Profits in a Time of Change.” *Journal of Oncology Practice*. 11, no. 1 (2015): e95–e97.
- Howard, D, PB Bach, ER Berndt, and RM Conti. “Pricing in the Market for Anticancer Drugs.” *Journal of Economic Perspectives*. 29, no. 1, (2015): 139–62.
- Conti, RM, WV Padula, and RA Larson. “Changing the Cost of Care for Chronic Myeloid Leukemia: The Availability of Generic Imatinib in the US and the EU.” *Annals of Hematology*. 94 Suppl. 2 (2015): S249–57. Epub Mar. 27, 2015.
- Dusetzina, SB, S Ellis, RA Freedman, RM Conti, AN Winn, JD Chambers, GC Alexander, HA Huskamp, and NL Keating. “How Do Payers Respond to Regulatory Actions? The Case of Bevacizumab.” *Journal of Oncology Practice*. 11, no. 4 (2015): 313–18. Epub June 9, 2015.
- Conti, RM. “The Advantages of Awarding the Federal Government Negotiating Power over the Prices of Prescription Drugs—Point-Counterpoint: Should Medicare Regulate the Price of Prescription Drugs?” *Journal of Policy Analysis and Management*. 35 (2016): 964–70.
- Conti, RM. “Response to Joyce and Sood: Why Medicare Price Negotiation Is the Wrong Prescription for Rising Drug Spending, Point-Counterpoint: Should Medicare Regulate the Price of Prescription Drugs?” *Journal of Policy Analysis and Management*. 35 (2016): 972–74.
- Conti, RM, and MB Rosenthal. “Pharmaceutical Policy Reform—Balancing Affordability with Incentives for Innovation.” *New England Journal of Medicine*. 374, no. 8 (2016): 703–06.
- Bach, PB, RM Conti, RJ Muller, GC Schnorr, and LB Saltz. “Overspending Driven by Oversized Single Dose Vials of Cancer Drugs.” *The BMJ*. 352 (2016): i788.
- Weiner, AB, RM Conti, and SE Eggener. “National Economic Conditions and Patient Insurance Status Predict Prostate Cancer Diagnosis Rates and Management Decisions.” *Journal of Urology*. 195, no. 5 (2016): 1383–89. Epub Dec. 18, 2015.

- Clark, B, JG Hou, ES Huang, RM Conti, and C Chou. “Medication Adherence among HIV/AIDS Patients Receiving 340B-Purchased Antiretroviral Medications.” *Value in Health*. 19, no. 3 (2016): A8.
- Polite, B, JC Ward, JV Cox, RF Morton, J Hennessy, R Page, and RM Conti. “A Pathway through the Bundle Jungle.” *Journal of Oncology Practice*. 12, no. 6 (2016): 504–09. Epub May 12, 2016.
- Padula, WV, RA Larson, SB Dusetzina, JF Apperley, R Hehlmann, M Baccarani, E Eigendorff, J Guilhot, F Guilhot, R Hehlmann, FX Mahon, G Martinelli, J Mayer, MC Müller, D Niederwieser, S Saussele, CA Schiffer, RT Silver, B Simonsson, and RM Conti. “Cost-Effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States.” *Journal of the National Cancer Institute*. 108, no. 7 (2016).
- Pitts, PJ, HL Louet, Y Moride, and RM Conti. “21st Century Pharmacovigilance: Efforts, Roles, and Responsibilities.” *Lancet Oncology*. 17, no. 11 (2016): e486–e492.
- Conti, RM, RE Gee, and JM Sharfstein. “Pharmaceuticals and Public Health.” *Journal of the American Medical Association*. 316, no. 20 (2016):2083–84.
- Chua, KP, AL Schwartz, A Volerman, RM Conti, and ES Huang. “Use of Low-Value Pediatric Services among the Commercially Insured.” *Pediatrics*. 138, no. 6 (2016). Erratum in *Pediatrics*. 139, no. 3 (2017).
- Conti, RM, and DK Jones. “Policy Diffusion across Disparate Disciplines: Private- and Public-Sector Dynamics Affecting State-Level Adoption of the ACA.” *Journal of Health Politics, Policy, and Law*. 42, no. 2 (2017): 377–85. Epub Dec. 22, 2016.
- Chua, KP, and RM Conti. “Out-of-Pocket Spending among Commercially Insured Patients for Epinephrine Autoinjectors between 2007 and 2014.” *Journal of the American Medical Association Internal Medicine*. 177, no. 5 (2017):736–39.
- de Souza, JA, and RM Conti. “Mitigating Financial Toxicity among US Patients with Cancer.” *Journal of the American Medical Association Oncology*. 3, no. 6 (2017):765–66.
- Dusetzina, SB, RM Conti, NL Yu, and PB Bach. “Association of Prescription Drug Price Rebates in Medicare Part D with Patient Out-of-Pocket and Federal Spending.”

- Journal of the American Medical Association Internal Medicine*. 177, no. 8 (2017): 1185–88.
- Conti, RM. “Biosimilars: Reimbursement Issues in Your Oncology Practice.” *Journal of Oncology Practice*. 13, no. 9_suppl (2017): 12s–14s.
 - Chua, KP, MG Shrimel, and RM Conti. “Effect of FDA Investigation on Opioid Prescribing to Children after Tonsillectomy/Adenoidectomy.” *Pediatrics*. 140, no. 6 (2017).
 - Chua, KP, RM Conti, and G Freed. “Appropriately Framing Child Health Care Spending: A Prerequisite for Value Improvement.” *Journal of the American Medical Association*. 319, no. 11 (2018): 1087–88.
 - Berndt, ER, RM Conti, and SJ Murphy. “The Generic Drug User Fee Amendments: An Economic Perspective.” *Journal of Law and the Biosciences*. 5, no. 1 (2018): 103–141.
 - Nikpay, S, M Buntin, and RM Conti. “Diversity of Participants in the 340B Drug Pricing Program for US Hospitals.” *Journal of the American Medical Association Internal Medicine*. 178, no. 8 (2018): 1124–27.
 - Chua KP, Conti RM. Out-of-pocket Spending on Orphan Drug Prescriptions Among Commercially Insured Adults in 2014. *J Gen Intern Med*. 2018 Oct 15.
 - Conti RM, Nguyen KH, Rosenthal MB. Generic prescription drug price increases: which products will be affected by proposed anti-gouging legislation? *J Pharm Policy Pract*. 2018 Nov 21;11:29.
 - Chua KP, Conti RM. Out-of-pocket Spending on Orphan Drug Prescriptions Among Commercially Insured Adults in 2014. *J Gen Intern Med*. 2019 Mar;34(3):338-340. doi: 10.1007/s11606-018-4694-1. PubMed PMID: 30324293; PubMed Central PMCID:PMC6420515.
 - Chua KP, Brummett CM, Conti RM, Haffajee RL, Prosser LA, Bohnert ASB. Assessment of Prescriber and Pharmacy Shopping Among the Family Members of Patients Prescribed Opioids. *JAMA Netw Open*. 2019 May 3;2(5):e193673. doi: 10.1001/jamanetworkopen.2019.3673. PubMed PMID: 31074819.
 - Royce TJ, Kircher S, Conti RM. Pharmacy Benefit Manager Reform: Lessons From Ohio. *JAMA*. 2019 Jun 20. doi: 10.1001/jama.2019.7104. [Epub ahead of print]

- PubMed PMID: 31219507.
- Woo JL, Anderson BR, Gruenstein D, Conti RM, Chua KP. Minimum travel distance among publicly insured infants with severe congenital heart disease: potential impact of in-state restrictions. *Pediatr Cardiol*. 2019 Aug 28. doi: 10.1007/s00246-019-02193-1. [Epub ahead of print]
 - Conti RM, Berndt ER. Four Facts Concerning Competition in U.S. Generic Prescription Drug Markets. *International Journal of the Economics of Business*. 2019 September 5. <https://www.tandfonline.com/doi/abs/10.1080/13571516.2019.1654324?journalCode=cijb20>
 - Conti RM, Nikpay SS, Buntin MB. Revenues and Profits from Medicare Patients in Hospitals Participating in the 340B Drug Discount Program, 2013-2016. *JAMA Netw Open*. 2019 Oct 2;2(10):e1914141. doi: 10.1001/jamanetworkopen.2019.14141. PubMed PMID: 31664442.
 - Vermeulen LC, Swarthout MD, Alexander GC, Ginsburg DB, Pritchett KO, White SJ, Tryon J, Emmerich C, Nesbit TW, Greene W, Fox ER, Conti RM, Scott BE, Sheehy F, Melby MJ, Lantzy MA, Hoffman JM, Knoer S, Zellmer WA. ASHP Foundation Pharmacy Forecast 2020: Strategic Planning Advice for Pharmacy Departments in Hospitals and Health Systems. *Am J Health Syst Pharm*. 2020 Jan 8;77(2):84-112. doi: 10.1093/ajhp/zxz283. PubMed PMID: 31803902.
 - Chen AJ, Hu X, Conti RM, Jena AB, Goldman DP. Trends in the Price per Median and Mean Life-Year Gained Among Newly Approved Cancer Therapies 1995 to 2017. *Value Health*. 2019 Dec;22(12):1387-1395. doi: 10.1016/j.jval.2019.08.005. Epub 2019 Sep 23. PubMed PMID: 31806195.
 - Chua KP, Brummett CM, Conti RM, Bohnert A. Association of Opioid Prescribing Patterns with Prescription Opioid Overdose in Adolescents and Young Adults. *JAMA Pediatr*. 2019 Dec 16. doi: 10.1001/jamapediatrics.2019.4878. [Epub ahead of print] PubMed PMID: 31841589; PubMed Central PMCID: PMC6990690.
 - Chua KP, Schwartz AL, Volerman A, Conti RM, Huang ES. Differences in the Receipt of Low-Value Services Between Publicly and Privately Insured Children.

- Pediatrics. 2020 Feb;145(2). pii: e20192325. doi: 10.1542/peds.2019-2325. Epub 2020 Jan 7. PubMed PMID: 31911477; PubMed Central PMCID: PMC6993279.
- Kimmel L, Conti RM, Volerman A, Chua KP. Pediatric Orphan Drug Indications: 2010-2018. *Pediatrics*. 2020 Apr;145(4). pii: e20193128. doi: 10.1542/peds.2019-3128. Epub 2020 Mar 3. PubMed PMID: 32127360; PubMed Central PMCID: PMC7111489.
 - Nikpay SS, Buntin MB, Conti RM. Relationship between initiation of 340B participation and hospital safety-net engagement. *Health Serv Res*. 2020 Apr;55(2):157-169. doi: 10.1111/1475-6773.13278. PubMed PMID: 32187392; PubMed Central PMCID: PMC7080377.
 - Chua KP, Lee JM, Conti RM. Out-of-pocket spending for insulin, diabetes-related supplies, and other health care services among privately insured US patients with type 1 diabetes. *JAMA Intern Med*. 2020 Jul 1; 180(7): 1012-1014. Doi: 10.1001/jamainternmed.2020.1308.PMID 32478819.
 - Chua KP, Lee JM, Conti RM. Potential changes in insulin out-of-pocket spending under cost-sharing caps among pediatric patients with type 1 diabetes. *JAMA Pediatr*. 2020 Jul 27:e201065. Doi:10.1001/jamapediatrics.2020.1065.
 - Padula WV, Parasrampur S, Socal MP, Conti RM, Anderson GF. Market Exclusivity for Drugs with Multiple Orphan Approvals (1983-2017) and Associated Budget Impact in the US. *Pharmacoeconomics*. 2020 Oct; 38(10): 1115-1121. Doi: 10.1007/s40273-020-00934-2.PMID: 32533523.
 - Padula WV, Parasrampur S, Socal MP, Conti RM, Anderson GF. Reply to Comment on “Market Exclusivity for Drugs with Multiple Orphan Approvals (1983-2017) and Associated Budget Impact in the US”. *Pharmacoeconomics*. 2020 Nov 9. Doi: 10.1007/s40273-020-00973-9. PMID: 33164137.
 - Chua KP, Fendrick AM, Conti RM, Moniz MH. Out-of-Pocket Spending for Deliveries and Newborn Hospitalizations Among the Privately Insured. *Pediatrics*. 2021 Jul;148(1):e2021050552. doi: 10.1542/peds.2021-050552. Epub 2021 Jun 17.PMID: 34140392

- Mattingly TJ 2nd, Seo D, Ostrovsky AM, Vanness DJ, Conti RM. 60 Years after Kefauver: Household income required to buy prescription drugs in the United States and abroad. *Res Social Adm Pharm.* 2021 Aug;17(8):1489-1495. doi: 10.1016/j.sapharm.2020.11.007. Epub 2020 Nov 16.PMID: 33221266
- Chua KP, Volerman A, Conti RM. Prescription Drug Dispensing to US Children During the COVID-19 Pandemic. *Pediatrics.* 2021 Aug;148(2):e2021049972. doi: 10.1542/peds.2021-049972. Epub 2021 Jul 20.PMID: 34285080
- Conti RM, Padula WV, Becker RV, Salamone S. The cost-effectiveness of therapeutic drug monitoring for the prescription drug-based treatment of chronic myeloid leukemia. *J Manag Care Spec Pharm.* 2021 Aug;27(8):1077-1085. doi: 10.18553/jmcp.2021.27.8.1077.PMID: 34337991
- Chua KP, Brummett CM, Conti RM, Bohnert AS. Opioid Prescribing to US Children and Young Adults in 2019. *Pediatrics.* 2021 Sep;148(3):e2021051539. doi: 10.1542/peds.2021-051539. Epub 2021 Aug 16.PMID: 34400571
- Chua KP, Conti RM, Becker NV. Assessment of Out-of-Pocket Spending for COVID-19 Hospitalizations in the US in 2020. *JAMA Netw Open.* 2021 Oct 1;4(10):e2129894. doi: 10.1001/jamanetworkopen.2021.29894.PMID: 34661662
- Chua KP, Conti RM. *Prescriptions for Codeine or Hydrocodone Cough and Cold Medications to US Children and Adolescents Following US Food and Drug Administration Safety Communications.* *JAMA Netw Open.* 2021 Nov 1;4(11):e2134142. doi: 10.1001/jamanetworkopen.2021.34142.PMID: 34762115
- Conti RM, Frank RG, Gruber J. Regulating Drug Prices while Increasing Innovation. *N Engl J Med.* 2021 Nov 18;385(21):1921-1923. doi: 10.1056/NEJMp2113764. Epub 2021 Nov 13.PMID: 34767322
- Chua KP, Dahlem CHY, Nguyen TD, Brummett CM, Conti RM, Bohnert AS, Dora-Laskey AD, Kocher KE. Naloxone and Buprenorphine Prescribing Following US Emergency Department Visits for Suspected Opioid Overdose: August 2019 to April 2021. *Ann Emerg Med.* 2021 Nov 18:S0196-0644(21)01349-4. doi: 10.1016/j.annemergmed.2021.10.005. Online ahead of print.PMID: 34802772

- Maldonado JA, Fu S, Chen YS, Acquati C, Yabroff KR, Banegas MP, Chang S, Conti RM, Checka CM, Peterson SK, Advani P, Ku K, Jagsi R, Giordano SH, Volk RJ, Shih YT, Smith GL. Sensitivity of Psychosocial Distress Screening to Identify Cancer Patients at Risk for Financial Hardship During Care Delivery. *JCO Oncol Pract*. 2021 Dec;17(12):e1856-e1865. doi: 10.1200/OP.20.01009. Epub 2021 May 27. PMID: 34043452
- Frank R, Conti RM, Gruber J. International Reference Pricing in the Context of US Drug Policy. *J Health Polit Policy Law*. 2022 Dec 1;47(6):779-796. doi: 10.1215/03616878-10041177. PMID: 35867549.
- Sharfstein JM, Conti RM, Gee RE. From COVID Vaccines to HIV Prevention: Pharmaceutical Financing and Distribution for the Public's Health. *J Law Med Ethics*. 2022;50(S1):29-31. doi: 10.1017/jme.2022.32. PMID: 35902083; PMCID: PMC9341206.
- Ballreich J, Levengood T, Conti RM. Opportunities and Challenges of Generic Pre-Exposure Prophylaxis Drugs for HIV. *J Law Med Ethics*. 2022;50(S1):32-39. doi: 10.1017/jme.2022.33. PMID: 35902088; PMCID: PMC9341204.
- Chua KP, Fendrick AM, Conti RM, Moniz MH. Prevalence and Magnitude of Potential Surprise Bills for Childbirth. *JAMA Health Forum*. 2021 Jul 2;2(7):e211460. doi: 10.1001/jamahealthforum.2021.1460. PMID: 35977212; PMCID: PMC8796895.
- Conti RM, Frank RG, Nichols LM. How Do Commercial Insurance Plans Fare Under Proposed Prescription Drug Price Regulation? *JAMA Health Forum*. 2021 Dec 3;2(12):e214242. doi: 10.1001/jamahealthforum.2021.4242. PMID: 36218917.
- Chua KP, Conti RM, Becker NV. Trends in and Factors Associated With Out-of-Pocket Spending for COVID-19 Hospitalizations From March 2020 to March 2021. *JAMA Netw Open*. 2022 Feb 1;5(2):e2148237. doi: 10.1001/jamanetworkopen.2021.48237. PMID: 35157059; PMCID: PMC8845007.
- Chua KP, Conti RM, Becker NV. US Insurer Spending on Ivermectin Prescriptions for COVID-19. *JAMA*. 2022 Feb 8;327(6):584-587. doi: 10.1001/jama.2021.24352. PMID: 35024763; PMCID: PMC8759024.

- Chua KP, Dahlem CHY, Nguyen TD, Brummett CM, Conti RM, Bohnert AS, Dora-Laskey AD, Kocher KE. Naloxone and Buprenorphine Prescribing Following US Emergency Department Visits for Suspected Opioid Overdose: August 2019 to April 2021. *Ann Emerg Med.* 2022 Mar;79(3):225-236. doi: 10.1016/j.annemergmed.2021.10.005. Epub 2021 Nov 19. PMID: 34802772; PMCID: PMC8860890.
- Mattingly TJ 2nd, Conti RM. Ensuring a high-quality and resilient supply chain of essential medications means paying more. *J Manag Care Spec Pharm.* 2022 May;28(5):573-576. doi: 10.18553/jmcp.2022.28.5.573. PMID: 35471068.
- Chua KP, Conti RM. Out-of-Pocket Spending on Epinephrine Auto-Injectors Among the Privately Insured, 2015-2019. *J Gen Intern Med.* 2022 Jul 11. doi: 10.1007/s11606-022-07694-z. Epub ahead of print. PMID: 35819685.
- Corrigan KL, Fu S, Chen YS, Kaiser K, Roth M, Peterson SK, Shih YT, Jagsi R, Giordano SH, Volk RJ, Yabroff KR, Banegas MP, Acquati C, Conti RM, Ma HY, Ku K, You YN, Smith GL. Financial toxicity impact on younger versus older adults with cancer in the setting of care delivery. *Cancer.* 2022 Jul 1;128(13):2455-2462. doi: 10.1002/cncr.34220. Epub 2022 Apr 13. PMID: 35417565; PMCID: PMC9177670.
- Chua KP, Conti RM, Becker NV. Out-of-pocket spending for health care after COVID-19 hospitalization. *Am J Manag Care.* 2022 Aug;28(8):398-402. doi: 10.37765/ajmc.2022.88852. PMID: 35981125; PMCID: PMC9826666.
- Smith GL, Banegas MP, Acquati C, Chang S, Chino F, Conti RM, Greenup RA, Kroll JL, Liang MI, Pisu M, Primm KM, Roth ME, Shankaran V, Yabroff KR. Navigating financial toxicity in patients with cancer: A multidisciplinary management approach. *CA Cancer J Clin.* 2022 Sep;72(5):437-453. doi: 10.3322/caac.21730. Epub 2022 May 18. PMID: 35584404.
- Nathan PC, Huang IC, Chen Y, Henderson TO, Park ER, Kirchoff AC, Robison LL, Krull K, Leisenring W, Armstrong GT, Conti RM, Yasui Y, Yabroff KR. Financial Hardship in Adult Survivors of Childhood Cancer in the Era After Implementation of the Affordable Care Act: A Report From the Childhood Cancer Survivor Study. *J Clin*

- Oncol. 2022 Sep 30;JCO2200572. doi: 10.1200/JCO.22.00572. Epub ahead of print. PMID: 36179267.
- Levenson TW, Aronson AI, Chua KP, Conti RM. Dispensing of HIV and Hepatitis C Antivirals During COVID-19: An Interrupted Time-Series Analysis of U.S. National Data. *Am J Prev Med.* 2022 Oct;63(4):532-542. doi: 10.1016/j.amepre.2022.04.024. Epub 2022 May 20. PMID: 35738958; PMCID: PMC9119965.
 - Akesson J, Weiss ES, Sae-Hau M, Gracia G, Lee M, Culp L, Connell B, Butterfield S, Conti RM. COVID-19 Vaccine-Related Beliefs and Behaviors Among Patients With and Survivors of Hematologic Malignancies. *JCO Oncol Pract.* 2022 Nov 9;OP2200338. doi: 10.1200/OP.22.00338. Epub ahead of print. PMID: 36351207.
 - Auty SG, Griffith KN, Shafer PR, Gee RE, Conti RM. Improving Access to High-Value, High-Cost Medicines: The Use of Subscription Models to Treat Hepatitis C Using Direct-Acting Antivirals in the United States. *J Health Polit Policy Law.* 2022 Dec 1;47(6):691-708. doi: 10.1215/03616878-10041121. PMID: 35867531; PMCID: PMC9789167.
 - Becker NV, Seelye S, Chua KP, Echevarria K, Conti RM, Prescott HC. Dispensing of Ivermectin From Veterans Administration Pharmacies During the COVID-19 Pandemic. *JAMA Netw Open.* 2023 Feb 1;6(2):e2254859. doi: 10.1001/jamanetworkopen.2022.54859. PMID: 36723943.
 - Butterfield S, Conti RM. COVID-19 Vaccine-Related Beliefs and Behaviors Among Patients With and Survivors of Hematologic Malignancies. *JCO Oncol Pract.* 2023 Feb;19(2):e167-e175. doi: 10.1200/OP.22.00338. Epub 2022 Nov 9. PMID: 36351207; PMCID: PMC9970299.
 - Hager A, Gracia G, Rodin D, Conti RM. Out-of-Pocket Costs of Treatment Among Employer-Insured Women With Invasive Breast Cancer. *JAMA Netw Open.* 2023 Mar 1;6(3):e231507. doi: 10.1001/jamanetworkopen.2023.1507. PMID: 36867412; PMCID: PMC9984972.
 - Chua KP, Nguyen TD, Zhang J, Conti RM, Lagisetty P, Bohnert AS. Trends in Buprenorphine Initiation and Retention in the United States, 2016-2022. *JAMA.* 2023

Apr 25;329(16):1402-1404. doi: 10.1001/jama.2023.1207. PMID: 37097363;
PMCID: PMC10130945.

A.6.b. Working papers

- Conti, RM, HA Huskamp, and ER Berndt. “The Effect of FDA Advisories on Branded Pharmaceutical Firms’ Valuations and Promotion Efforts.” NBER Working Paper No. 17528. October 2011. *Available at:* <http://www.nber.org/papers/w17528>.
- Conti, RM, and ER Berndt. “Specialty Drug Prices and Utilization after Loss of US Patent Exclusivity, 2001–2007.” NBER Working Paper No. 20016. March 2014. *Available at:* <http://www.nber.org/papers/w20016>.
- Berndt, ER, RM Conti, and SJ Murphy. “The Landscape of US Generic Prescription Drug Markets, 2004–2016.” NBER Working Paper No. w23640. July 2017. *Available at:* <http://www.nber.org/papers/w23640>.
- Berndt, ER, RM Conti, and SJ Murphy. “The Generic Drug User Fee Amendments: An Economic Perspective.” NBER Working Paper No. w23642. August 2017. *Available at:* <http://www.nber.org/papers/w23642>.
- Conti RM, Berndt ER. Four Facts Concerning Competition in U.S. Generic Prescription Drug Markets. NBER Working Paper No. 26194. August 2019. *Available at:* <https://www.nber.org/papers/w26194>.
- Conti RM, Gruber J, Ollendorf D, Neumann P. Valuing Rare Pediatric Drugs: An Economics Perspective. October 2020. NBER Working Paper 27978.
- Wong CH, Li D, Wang N, Gruber J, Conti RM, Lo AW. Estimating the Financial Impact of Gene Therapy in the U.S. NBER Working Paper No. 28628. April 2021. *Available at:* <https://www.nber.org/papers/w28628>.
- Park M, Tucker A, Fox E, Conti RM. Stockpiling Medicines at the Onset of the COVID-19 Pandemic: An Empirical Analysis of National Prescription Drug Sales and Prices. December 2021. *Available at:* https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3988183.
- Conti RM, Frandsen B, Powell ML, Rebitzer JB. Common Agent or Double Agent? Pharmacy Benefit Managers in the Prescription Drug Market. NBER Working Paper No.

28866. May 2021. Revised June 2022. Available at:
<https://www.nber.org/papers/w28866>.

A.6.c. Non-peer-reviewed original articles (selected, not comprehensive)

- Conti, RM. “Smallpox Vaccinations: The Risks and the Benefits.” Policy brief for the John F. Kennedy School of Government, Harvard University/Commonwealth Fund Bipartisan Congressional Health Policy Conference, January 2003, Aventura, Florida. Invited issue brief, *Commonwealth Fund*. 2003. Available at:
<http://www.commonwealthfund.org/publications/issue-briefs/2003/apr/smallpox-vaccinations--the-risks-and-the-benefits>.
- Conti, RM. “Balancing Safety, Effectiveness, and Public Desire: The FDA and Cancer.” Invited issue brief, *Commonwealth Fund*. 2003. Available at:
<http://www.commonwealthfund.org/publications/issue-briefs/2003/apr/balancing-safety--effectiveness--and-public-desire--the-fda-and-cancer>.
- Conti, RM. Invited guest editorial. “FDA Must Address Economic Incentives to Resolve Drug Shortages Permanently.” *The Cancer Letter*. Feb. 28, 2012. Available at: http://www.cancerletter.com/articles/20120228_1.
- Conti, RM. Invited guest editorial. “FDA’s Recently Announced Policies to Help Relieve Drug Shortages Are an Important First Step, But Some Questions Remain: A Health Economist’s Perspective.” *The Cancer Letter*. Mar. 3, 2012. Available at: <http://cancerletter.com/articles/20120302>.
- Conti, RM. Invited news analysis. “The Political Economy of Importations to Alleviate Cancer Drug Shortages.” *The Cancer Letter*. Mar. 5, 2012. Available at: http://www.cancerletter.com/articles/20120305_1.
- Conti, RM. Invited guest editorial. “Recent Public Policy Progress on Addressing the Drug Shortage Crises.” *The Cancer Letter*. June 25, 2012. Available at: <http://cancerletter.com/articles/20120622>.
- Conti, RM. Invited news analysis. “Industry’s Accelerated Recovery Initiative May Push Manufacturers toward Collusion.” *The Cancer Letter*. Oct. 9, 2012. Available at: http://www.cancerletter.com/articles/20121009_1.

- Conti, RM, and ER Berndt. “Winners and Losers of the Zaltrap Price Discount.” *Health Affairs (Millwood)*. Blog. Feb. 22, 2013. Available at: <http://healthaffairs.org/blog/2013/02/20/winners-and-losers-from-the-zaltrap-price-discount-unintended-consequences/>.
- Conti, RM. “Why Are Cancer Drugs Commonly the Target of Numerous Schemes to Extend Patent Exclusivity?” *Health Affairs (Millwood)*. Blog. Dec. 4, 2013. Available at: <http://healthaffairs.org/blog/2013/12/04/why-are-cancer-drugs-commonly-the-target-of-schemes-to-extend-patent-exclusivity/>.
- Conti, RM, ER Berndt, and D Howard. “Cancer Drug Prices Rise with No End in Sight.” *Vox*. Mar. 25, 2015. Available at: <http://www.voxeu.org/article/cancer-drug-prices-rise-no-end-sight>.
- Conti, RM, RH Glassman, and MJ Ratain. “New Cures Require New Pricing Policies.” *Health Affairs (Millwood)*. Blog. Apr. 16, 2015. Available at: <http://healthaffairs.org/blog/2015/04/16/new-cures-require-new-pricing-policies/>.
- Conti, RM, MB Landrum, and M Jacobson. “The Impact of Provider Consolidation on Outpatient Prescription Drug-Based Cancer Care Spending.” *Health Care Cost Institute*. 2016. Available at: <http://www.healthcostinstitute.org/files/HCCI-Issue-Brief-Impact-of-Provider-Consolidation.pdf>.
- Conti, RM. “Value in Cancer Care: An Economist’s Perspective.” *American Journal of Managed Care*. Oncology Stakeholders Summit Supplement, Spring 2016. Available at: <http://www.ajmc.com/journals/evidence-based-oncology/2016/Peer-Exchange-Spring-2016-Oncology-Stakeholders-Summit>.
- Sharfstein J, J Lee, and RM Conti. “Hepatitis C in Louisiana.” *Vox*. Sept. 27, 2017. Available at: <https://www.vox.com/science-and-health/2017/9/27/16350562/hepatitis-c-drug-prices-louisiana>.
- Nikpay S, MB Buntin, and RM Conti. “The 340B Program: Mandatory Reporting, Alternative Eligibility Criteria Should Be Top Priorities for Congress.” *Health Affairs (Millwood)*. Blog. Oct. 10, 2017. Available at: <http://www.healthaffairs.org/doi/10.1377/hblog20171021.982593/full/>.

- Conti, RM. “Making Medicines Affordable: A National Imperative—A Review.” *Health Affairs (Millwood)*. Blog. Nov. 30, 2017. Available at: <https://www.healthaffairs.org/action/showDoPubSecure?doi=10.1377%2Fhblog20171130.861415&format=full>.
- Conti RM, and D Lakdawalla. “Putting More Value into Biopharmaceutical Value Assessments.” *Health Affairs (Millwood)*. Blog. Jan. 3, 2018. Available at: <https://www.healthaffairs.org/action/showDoPubSecure?doi=10.1377%2Fhblog20171227.196339&format=full>.
- Conti RM, David FS. “Rebalancing High Prescription Drug Prices With Innovation Incentives.” *Health Affairs (Millwood)*. Blog. July 1, 2019. Available at: <https://www.healthaffairs.org/do/10.1377/hblog20190626.569971/full/>
- Chua K-P, Conti RM. “Orphan Drugs For Opioid Use Disorder: An Abuse Of The Orphan Drug Act.” *Health Affairs (Millwood)*. Blog. July 26, 2019. Available at: <https://www.healthaffairs.org/do/10.1377/hblog20190724.795814/full/>
- Conti RM, P Kleutghen. “Is ‘Competitive Licensing’ Proposed In HR 1046 Practical For Lowering Drug Prices?” *Health Affairs (Millwood)*. Blog. July 29, 2019. Available at: <https://www.healthaffairs.org/do/10.1377/hblog20190724.85223/full/>
- Conti RM. Financial Toxicity of Prescription Drugs. *Ann Intern Med*. 2019 Oct 1. doi: 10.7326/M19-2899. [Epub ahead of print] PubMed PMID: 31569210.
- Conti RM. 3 Things You Need to Know About Prescription Drug Affordability. IHSIP weblog October 2019
- Conti RM. The Orphan Drug Act: IHSIP Expertise in Policy Action. Kaiser Family Foundation weblog October 2019.
- Conti RM, Sharfstein J. Make vaccines and drugs to treat coronavirus accessible to all. *The Incidental Economist*, March 10 2020 <https://theincidentaleconomist.com/wordpress/make-vaccines-and-drugs-to-treat-coronavirus-accessible-to-all/>
- Chua K-P, Conti RM, Despite the Families First Coronavirus Response Act, COVID-19 Evaluation Is Not Necessarily Free. *Health Affairs (Millwood)*. Blog. April 2020.

- Gracia G, David F, Conti RM. Incentives For Drug R&D: A Survey Of Biotech Venture Capitalists' Perspectives. *Health Affairs Forefront*. July 2022.

A.6.d. Book chapters

- Conti, RM, RG Frank, and TG McGuire (2004). “Insuring Mental Health Care in the Age of Managed Care.” In *Mental Health Services: A Public Health Perspective*, 2nd ed., edited by Bruce Lubotsky Levin, John Petrila, Kevin D. Hennessy, 15–41. New York: Oxford University Press, 2004.
- Conti, RM, ER Berndt, and RG Frank. “Retirement and Disability Insurance Applications: Exploring the Impact of Depression.” In *Health in Older Ages: The Causes and Consequences of Declining Disability among the Elderly*, edited by David M. Cutler and David Wise, 381–410. Chicago: University of Chicago Press, 2008.
- Conti, RM, AB Bernstein, and DO Meltzer. “How Do Initial Signals of Quality Influence the Diffusion of New Medical Products? The Case of New Cancer Treatments.” In *Advances in Health Economics & Health Services*, vol. 23, edited by K Bolin and R Kaestner. Bingley, UK: Emerald Group Publishing, 2012.
- Conti, RM, and DO Meltzer. “Value of Information Methods to Prioritize Research: Opportunities and Challenges for Practical Application.” In *Encyclopedia of Health Economics*, edited by Anthony J. Culyer, 441–45. Amsterdam: Elsevier, 2014.
- Polite, B, RM Conti, and JC Ward. “Reform of the Buy-and-Bill System for Outpatient Chemotherapy Care Is Inevitable: Perspectives from an Economist, a Realpolitik, and an Oncologist.” In *American Society of Clinical Oncology Educational Book*, vol. 35, e75–80. Alexandria, VA: ASCO, 2015.
- Conti, RM, and ER Berndt. “Specialty Drug Prices and Utilization after Loss of U.S. Patent Exclusivity, 2001–2007.” In *Advances in CRIW Conference Proceedings*. September 2017. Available at: <http://papers.nber.org/books/aizc13-1>.
- Conti, RM, WV Padula, and RA Larson (2016). “Changing the Cost of Care for Chronic Myeloid Leukemia: The Availability of Generic Imatinib in the U.S. and the E.U.” In *Chronic Myeloid Leukemia: What Every Clinical Practitioner Needs to*

Know in 2017, edited by HJ Khoury, LA Williams, E Attalah, and R Hehlmann, 231–55. Alexandria, VA: ASCO, 2017. DOI: 10.1007/978-3-319-33198-0_15.

A.6.e. Media mentions (selected, not comprehensive)

- Previous to 2017
 - “Sen. Max Baucus Holds a Hearing on Drug Shortages.” *Political Transcript Wire* Dec. 8, 2011.
 - Bompey, Nanci. “Wyden Hopes to Work with Hatch on Bipartisan Solution to Drug Shortages.” Insidehealthpolicy.Com’s *Inside Health Reform*. 3, No. 50 (2011).
 - “New Health Economic Research Demonstrates Continued Value in Orphan Drug Act Incentives.” *PR Newswire*. Oct 7, 2013.
 - Toland, Bill. “UPMC ‘Moves’ Hillman for Chemotherapy Savings.” TCA Regional News. June 10, 2014.
 - “The Cost of Treating Cancer Skyrockets When Doctors Merge with Hospitals.” Fox News. Aug. 6, 2014. Available at: <http://www.Foxnews.Com/Health/2014/08/06/Cost-Treating-Cancer-Skyrockets-When-Doctors-Merge-With-Hospitals.Html>.
 - Gebhart, Fred. “The Ups and Downs of Generics.” *Drug Topics* 158, No. 8 (2014): 3–4s, 6s, 7s.
 - Westphal, Sylvia Pagan. “Writing a New Prescription for Costly Cures.” *The Boston Globe*. Sept. 14, 2014.
 - Wesphal, Sylvia Pagan. “Drug Pricing: A New Prescription.” *The Boston Globe*. Sept. 14, 2014. Available at: <https://www.Bostonglobe.Com/Opinion/2014/09/13/Drug-Pricing-New-Prescription/Iazrb2asexuqwy5yznqcjn/Story.Html>.
 - Easton, John. “Cancer Medicine: New, Improved, Expensive and Exploited?” *Science Life*. Oct. 7, 2014. Available at: <https://Sciencelife.Uchospitals.Edu/2014/10/07/Cancer-Medicine-New-Improved-Expensive-And-Exploited/>.

- Lee, Jaimy, and Adam Rubenfire. “Study: 340b Drug Program Aids Wealthier Communities.” *Modern Healthcare*. 44, No. 41 (2014): 8.
- London, Susan. “Tough Questions about Health-Care Reform Put Economist in Hot Seat.” *The ASCO Post*. Oct. 15, 2014. *Available at*:
<http://www.Ascopost.Com/Issues/Oct-15-2014/Tough-Questions-About-Health-Care-Reform-Put-Economist-In-Hot-Seat/>.
- Gorenstein, Dan. “The Shocking Cost of Wasted Prescription Pills.” *Marketplace*. Dec. 10, 2014. *Available at*: <https://www.Marketplace.Org/2014/12/10/Health-Care/Shocking-Cost-Wasted-Prescription-Pills>.
- Taylor, Timothy. “The Rising Price of Anti-Cancer Drugs.” *Conversable Economist*. Blog. Feb. 15, 2016.
- “The Future Cost of Cancer.” Accenture, Jan. 21, 2015. *Available at*:
<https://www.accenture.com/th-en/insight-perspectives-life-sciences-future-cost-cancer>.
- Hirst, Ellen Jean. “How Newest Drugs Could Save Billions.” *Chicago Tribune*. Mar. 22, 2015.
- Hirst, Ellen Jean. “Biosimilars Offer Vast Potential.” *The Ledger*. Mar. 28, 2015.
- Hirst, Ellen Jean. “Biosimilars.” *Bozeman Daily Chronicle*. Mar. 29, 2015.
- “Massachusetts Institute of Technology Study: Prices of Cancer Drugs Have Soared Since 1995.” *Biotech Business Week*. Mar. 30, 2015, 135.
- Nordrum, Amy. “Why Are Prescription Drugs So Expensive? Big Pharma Points to the Cost of Research and Development, Critics Say That’s No Excuse.” *International Business Times*. May 19, 2015. *Available at*:
<http://www.ibtimes.com/why-are-prescription-drugs-so-expensive-big-pharma-points-cost-research-development-1928263>.
- Sachdev, Ameet. “Cancer Doctors Sound Alarm over Crushing Costs of New Drugs.” *Chicago Tribune*. May 22, 2015. *Available at*:
<http://www.chicagotribune.com/business/ct-cancer-costs-0526-biz--20150522-story.html>.

- Sachdev, Ameet. “Cancer Doctors Sound Alarm over Crushing Costs of New Drugs.” *TCA Regional News*. May 23, 2015.
- Sachdev, Ameet. “Cancer Drugs Growing Costlier.” *Chicago Tribune*. May 26, 2015.
- Holman, Lane. “How Newest Class of Drugs Could Save Billions of Dollars.” *The Atlanta Journal-Constitution*. June 20, 2015. Available at: <http://www.myajc.com/classifieds/jobs/how-newest-class-drugs-could-save-billions-dollars/z7auzcqz21mrafh3cpotnj/>.
- Silverman, Stephanie. “Acquisitions by 340b Hospitals Drive Up Healthcare Costs.” Onclive, July 10, 2015. Available at: <http://www.onclive.com/web-exclusives/acquisitions-by-340b-hospitals-drive-up-healthcare-costs>.
- “Documents Released Showing IRS Scrutiny of Conservative Groups Going Beyond Tea Party Organizations; Cancer Hospitals Calling on Government to.” *Technology Wire*. July 23, 2015.
- “Documents Released Showing IRS Scrutiny of Conservative Groups Going Beyond Tea Party Organizations; Cancer Hospitals Calling on Government to.” *Finance Wire*. July 23, 2015.
- Taylor, Michelle. “The Rising Costs of Prescription Drugs.” *Laboratory Equipment*. Oct. 13, 2015.
- Schencker, Lisa. “PhRMA Beats Obama Administration Again in 340b Battle.” *Modern Healthcare*. 45, no. 42 (2015).
- Gorenstein, Dan. “Why Pharmaceutical Coupons Might Push Costs Up Overall.” *Marketplace*. Nov. 12, 2015. Available at: <https://www.marketplace.org/2015/11/12/tech/why-pharmaceutical-coupons-might-push-costs-overall>.
- “Broken Market for Old Drugs Means Price Spikes Are Here to Stay.” *Bloomberg*. Nov. 18, 2015. Available at: <https://www.bloomberg.com/news/articles/2015-11-18/the-law-of-pharma-pricing-physics-what-goes-up-often-stays-up>.

- Firth, Shannon. “D.C. Week: FDA Advisors Questions Dmd Drug; Rx \$\$\$—Again.” *Medpage Today*. Nov. 28, 2015. *Available at*:
<http://www.medpagetoday.com/washington-watch/washington-watch/54903>.
- Carroll, Lauren. “Bill Maher: Cancer Drugs Cost \$10,000 a Month.” *Tampa Bay Times*. Dec. 2, 2015.
- Carroll, Lauren. “Yes, Cancer Drug Prices Have Risen That Much.” *Tampa Bay Times*. Dec. 6, 2015.
- Sergel, Roger. “Will Amarin Case Put Judges in Charge of Drug Promotion?” *Medpage*. Feb. 1, 2016.
<https://www.medpagetoday.com/publichealthpolicy/fdageneral/55954>.
- “Report Links Health Care Mergers and Higher Costs.” *Marketplace*. Feb. 25, 2016. *Available at*: <https://www.marketplace.org/2016/02/24/health-care/report-links-health-care-mergers-and-higher-costs>.
- O’Donnell, Jayne. “Healthcare Deals May Boost Cancer Costs, While State Laws Stymie Telehealth.” *USA Today*. Feb. 25, 2016. *Available at*:
<https://www.usatoday.com/story/news/nation/2016/02/25/healthcare-deals-may-boost-cancer-costs-while-state-laws-stymie-telehealth/80861950/>.
- Karlin, Sarah, and Norman, Brett. “Opioid Bill Hits Senate Floor.” *Politico*. Feb 29, 2016. *Available at*: <http://www.politico.com/tipsheets/prescription-pulse/2016/02/opioid-bill-hits-senate-floor-scaling-back-340b-to-help-drug-pricingkyle-bass-pharma-patent-war-slows-down-212947>.
- Gorenstein, Dan. “Slashing Incentives to Prescribe Expensive Drugs.” *Marketplace*. Mar. 9, 2016. *Available at*:
<https://www.marketplace.org/2016/03/09/world/slashing-incentives-prescribe-expensive-drugs>.
- Johnson, Carolyn Y. “This Drug Is Defying a Rare Form of Leukemia—And It Keeps Getting Pricier.” *The Washington Post*, Mar. 9, 2016.
 - Johnson, Carolyn. “Drug Defies Cancer and Market Logic.” *Concord Monitor*. Mar. 13, 2016.

- “Using Generic Cancer Drug Could Save Many Millions of Dollars.” *Targeted News Service*. Mar. 15, 2016.
- “Using Generic Cancer Drug Could Save Many Millions Of Dollars.” Johns Hopkins Bloomberg School of Public Health News. Mar. 15, 2016. *Available at:* <http://www.jhsph.edu/news/news-releases/2016/using-generic-cancer-drug-could-save-many-millions-of-dollars.html>.
- Firth, Shannon. “ACP Calls on Government to Curb Drug Prices.” *Medpage Today*. Mar. 31, 2016. *Available at:* <http://www.medpagetoday.com/publichealthpolicy/generalprofessionalissues/57055>.
- “Generic Imatinib Cost-Effective First-Line Treatment for CML.” *Healio*. Apr. 7, 2016. *Available at:* <https://www.healio.com/hematology-oncology/leukemia/news/in-the-journals/%7b6ed7ed48-4741-4bd6-ace9-50578005de32%7d/generic-imatinib-cost-effective-first-line-treatment-for-cml>.
- Andrews, Michelle. “Rise in Oncologists Working for Hospitals Spurs Higher Chemo Costs: Study.” *Kaiser Health News*. Apr. 15, 2016. *Available at:* <http://khn.org/news/rise-in-oncologists-working-for-hospitals-spurs-higher-chemo-costs-study/>.
- Andrews, Michelle. “Study: Hospital Oncologists Push Chemo Costs Higher.” *Cincinnati Enquirer*. Apr. 24, 2016.
- Andrews, Michelle. “Study: Rise in Oncologists Working for Hospitals Spurs Higher Chemo Costs.” *TCA News Service*. May 13, 2016.
- Andrews, Michelle. “Rise in Oncologists Working for Hospitals Spurs Higher Chemo Costs.” *The Free Lance-Star*. May 22, 2016. *Available at:* http://www.fredericksburg.com/features/health_living/study-rise-in-oncologists-working-for-hospitals-spurs-higher-chemo/article_bbe4651f-515e-50a8-85df-5e96b66b54ea.html.
- Myers, Nan. “Concerns Persist About the 340b Program.” *Pharmacy Times*. May 31, 2016. *Available at:* <http://www.pharmacytimes.com/news/concerns-persist-about-the-340b-program>.

- Bennette, Caroline S., Catherine Richards, Sean D. Sullivan, and Scott D. Ramsey. “Steady Increase in Prices for Oral Anticancer Drugs after Market Launch Suggests a Lack of Competitive Pressure.” *Health Affairs* 35, No. 5 (2016): 805–812h.
Doi:<http://dx.doi.org.proxy.uchicago.edu/10.1377/hlthaff.2015.1145>.
- Hoffman, Jason. “More ‘Real-World’ Data Needed on Cost of Cancer Treatments.” *Cancer Therapy Advisor*. June 5, 2016. Available at: <http://www.cancertherapyadvisor.com/asco-2016/cancer-treatment-cost-real-world-data-needed/article/500977/>.
- Gorenstein, Dan. “Deals Aimed at Reining in Costs of Cancer Drugs Show Promise.” *Marketplace*. June 6, 2016. Available at: <https://www.marketplace.org/2016/06/03/health-care/deals-aimed-reining-costs-cancer-drugs-show-promise>.
- Johnson, Linda A. “Study Finds Lower-Priced Cancer Drugs Still Less Affordable in Poorer Nations.” *Charleston Gazette–Mail*. June 7, 2016.
- “United States: Cancer Drugs Less Affordable in Poor Nations than US.” *Asia News Monitor*. June 8, 2016.
- Jacobson, Louis. “Donald Trump Jr. Wrong That Hillary Clinton Is Proposing to Destroy Medicare.” *Tampa Bay Times*. July 19, 2016.
- Taylor, Leighton. “Howard Dean Largely Right On Mike Pence’s Health Policy Record.” *Tampa Bay Times*. Aug. 8, 2016.
- Robbins, Rebecca. “The Insulin Market Is Heading for a Shakeup. But Patients May Not Benefit.” *Stat*. Oct. 14, 2016. Available at: <https://www.statnews.com/2016/10/14/insulin-prices-generics/>.
- Mcginley, Laurie. “Many Medicare Cancer Patients Hit by High Out-of-Pocket Costs.” *The Washington Post*. Nov. 23, 2016. Available at: <https://www.washingtonpost.com/news/to-your-health/wp/2016/11/23/many-medicare-cancer-patients-hit-by-high-out-of-pocket-costs/>.
- Mcginley, Laurie. “Medicare Cancer Patients Face a Double Whammy.” *The Washington Post*. Nov. 24, 2016.

- Mcginley, Laurie. “Many Medicare Cancer Patients Pay High Costs.” *Dayton Daily News*. Nov. 27, 2016.
- Schencker, Lisa. “1 in 10 Got Unneeded Medical Services in 2014, U. Of C. Study Says.” *Chicago Tribune*. Dec. 1, 2016. Available at: <http://www.chicagotribune.com/business/ct-unnecessary-medical-services-kids-1209-biz-20161208-story.html>.
- “Study: Cancer Drug Prices Highest in US, Least Affordable in China, India.” Washington: The Advisory Board Company, 2016.
- “Study: Medicare Beneficiaries Can Face High Out-of-Pocket Costs for Cancer Treatment.” Washington: The Advisory Board Company, 2016.
- 2017
 - Schencker, Lisa. “Pharma Firm CEO Insists \$89,000 Drug Is Affordable, But What’s the True Cost?” *TCA Regional News*. Feb. 18, 2017.
 - Schencker, Lisa. “Questions Surround True Cost of \$89,000 Drug.” *Chicago Tribune*. Feb. 19, 2017.
 - Schencker, Lisa. “Pharma Firm CEO Insists \$89,000 Drug Is Affordable, But What’s the True Cost?” *Chicago Tribune*. Feb. 21, 2017. Available at: <http://www.chicagotribune.com/business/ct-high-drug-prices-marathon-muscular-dystrophy-0219-biz-20170217-story.html>.
 - Gillin, Joshua. “Fact-Checking Donald Trump’s Claim about Soaring Obamacare Premiums.” *Tampa Bay Times*. Feb. 28, 2017.
 - Gillin, Joshua. “Fact-Checking Donald Trump’s Claim about Soaring Obamacare Premiums.” *Politifact*. Feb. 28, 2017. Available at: <http://www.politifact.com/truth-o-meter/statements/2017/feb/28/donald-trump/fact-checking-donald-trumps-claim-about-soaring-ob/>.
 - Schencker, Lisa. “Marathon Sheds \$89,000 Muscular Dystrophy Drug after Pricing Uproar.” *Chicago Tribune*. Mar. 16, 2017. Available at: <http://www.chicagotribune.com/business/ct-marathon-sells-89000-drug-0317-biz-20170316-story.html>.

- Schencker, Lisa. “Marathon Sheds \$89,000 Muscular Dystrophy Drug after Pricing Uproar.” *TCA Regional News*. Mar. 17, 2017.
- Schencker, Lisa. “Northbrook Firm to Shed \$89k Drug.” *Chicago Tribune*. Mar. 17, 2017.
- “Patients Face Rising Costs for Epipen Allergy Drug.” *Science Daily*. Mar. 27, 2017. *Available at*:
<https://www.sciencedaily.com/releases/2017/03/170327172900.htm>.
- “Another Look at the Surge in Epipen Costs.” *Bangor Daily News*. Mar. 28, 2017. *Available at*: <https://bangordailynews.com/2017/03/28/news/nation/another-look-at-the-surge-in-epipen-costs/?ref=latest>.
- Liss, Samantha. “Express Scripts Battle with Anthem Raises Questions about Drug Prices.” *St. Louis Post-Dispatch*. May 7, 2017.
- Liss, Samantha. “Express Scripts Battle with Anthem Raises Questions about Drug Prices.” *TCA Regional News*. May 7, 2017.
- Liss, Samantha. “Express Scripts Battle with Anthem Raises Transparency Questions.” *TCA Regional News*. May 7, 2017.
- Elgin, Benjamin, Doni Bloomfield, and Caroline Chen. “When the Patient is a Gold Mine: The Trouble with Rare-Disease Drugs.” *Bloomberg*. May 24, 2017. *Available at*: <https://www.bloomberg.com/news/features/2017-05-24/when-the-patient-is-a-gold-mine-the-trouble-with-rare-disease-drugs>.
- “Drug Rebates Reward Industry Players—And Often Hurt Patients.” *Kaiser Health News*. May 30, 2017. *Available at*: <http://khn.org/news/drug-rebates-reward-industry-players-and-often-hurt-patients/>.
- Tribble, Sarah Jane. “Drug Rebates Reward Industry Players and Often Hurt Patients.” *TCA News Service*. May 30, 2017.
- Schencker, Lisa. “American Medical Association Urges Drug Companies to Advertise Prices.” *Chicago Tribune*. June 15, 2017. *Available at*:
<http://www.chicagotribune.com/business/ct-ama-drug-prices-0616-biz-20170615-story.html>.

- Schencker, Lisa. “American Medical Association Urges Drug Companies to Advertise Prices.” *TCA Regional News*. June 16, 2017.
- Schencker, Lisa. “Medical Association Wants Drug Costs in Ads.” *Chicago Tribune*. June 16, 2017.
- Langreth, Robert. “Popular Cancer Pill Goes Generic, Yet Patients’ Costs Stay High.” *Las Cruces Sun-News*. June 30, 2017.
- “Popular Cancer Pill Goes Generic, Yet Patients’ Costs Stay High.” *Bloomberg*. June 30, 2017. Available at: <https://www.bloomberg.com/news/articles/2017-06-30/popular-cancer-pill-goes-generic-yet-patients-costs-stay-high>.
- Johnson, Caroline Y. “The Generic Drug Industry Has Brought Huge Cost Savings. That May Be Changing.” *The Washington Post*. Aug. 2, 2017. Available at: https://www.washingtonpost.com/business/economy/the-generic-drug-industry-has-brought-huge-cost-savings-that-may-be-changing/2017/08/01/ee128d0a-68cf-11e7-8eb5-cbccc2e7bfbf_story.html?utm_term=.3cb8db13c9fe.
- Gorenstein, Dan. “Why Pharma Companies Are Bowing Out of Generics.” *Marketplace*. Aug. 2, 2017. Available at: <https://www.marketplace.org/2017/08/02/health-care/drug-prices-why-pharma-companies-are-bowing-out-generics>.
- Johnson, Carolyn Y. “Low Supplies, Price Spikes Limit Cost Savings of Generic Drugs.” *The Washington Post*, Aug. 2, 2017.
- “Generic Drug Biz Faces Unintended Consequences.” *The Washington Post*. Aug. 2, 2017. Available at: <https://www.medpagetoday.com/publichealthpolicy/healthpolicy/67029>.
- “Report Highlights Cracks in the Market for Generic Competition.” Regulatory Affairs Professional Society, Aug. 2, 2017. Available at: <http://www.raps.org/regulatory-focus/news/2017/08/02/28168/report-highlights-cracks-in-the-market-for-generic-competition/>.

- “Proposed Ordinance to Keep Close Watch on Rising Drug Prices in Chicago.” CBS, Chicago. Aug. 8, 2017. *Available at:* <http://chicago.cbslocal.com/2017/08/08/ordinance-drug-prices/>.
- “Financial Toxicity: Cancer Supportive Care Professionals Consider the Side Effects of Soaring Costs.” *The ASCO Post*. Aug. 10, 2017. *Available at:* <http://www.ascopost.com/issues/august-10-2017/financial-toxicity-cancer-supportive-care-professionals-consider-the-side-effects-of-soaring-costs/>.
- Lupkin, Sydney. “Rising Price of Old Drugs Costs Medicaid Billions.” *The Daily Beast*. Aug. 11, 2017.
- “Climbing Cost of Decades-Old Drugs Threatens to Break Medicaid Bank.” *Kaiser Health News*. Aug. 14, 2017. *Available at:* <http://khn.org/news/climbing-cost-of-decades-old-drugs-threatens-to-break-medicaid-bank/>.
- Lupkin, Sydney. “Climbing Cost of Decades-Old Drugs Threatens to Break Medicaid Bank.” *TCA News Service*. Aug. 15, 2017.
- Lupkin, Sydney. “Climbing Cost of Decades-Old Drugs Threatens Medicaid.” *TCA News Service*. Aug. 23, 2017.
- Johnson, Carolyn Y. “Sen. Bill Cassidy, a Liver Doctor, Grapples with Louisiana’s Liver Disease Crisis.” *The Washington Post*. July 5, 2017. *Available at:* https://www.washingtonpost.com/news/wonk/wp/2017/07/05/sen-bill-cassidy-a-liver-doctor-grapples-with-louisianas-liver-disease-crisis/?utm_term=.4ab7cb036076.
- Greene, Jeremy A. “Don’t Let Pharma Take Down a New Maryland Price Gouging Law.” *The Washington Post*. Sept. 8, 2017. *Available at:* https://www.washingtonpost.com/opinions/dont-let-big-pharma-take-down-a-new-maryland-price-gouging-law/2017/09/08/73a50630-8d99-11e7-84c0-02cc069f2c37_story.html?utm_term=.6c6d9a758850.
- Johnson, Carolyn Y. “Pfizer Sues Johnson & Johnson, Alleging Anticompetitive Practices to Maintain a Drug Monopoly.” *The Washington Post*. Sept. 20, 2017. *Available at:* <https://www.washingtonpost.com/news/wonk/wp/2017/09/20/pfizer->

sues-johnson-johnson-alleging-anticompetitive-practices-to-maintain-a-drug-monopoly/?utm_term=.7a3e0304257e.

- Ross, Casey. “Trump Takes on Hospitals: The Facts Behind Fight over 340B Drug Discounts.” *Statnews*. Nov. 6, 2017. *Available at*:
<https://www.statnews.com/2017/11/06/340b-drug-discounts-fight/>.
- Evans, Melanie. “Judge Dismisses Hospital-Industry Suit That Attempted to Stop Medicare-Subsidy Cuts.” *Wall Street Journal*. Dec. 29, 2017. *Available at*:
<https://www.wsj.com/articles/judge-dismisses-hospital-industry-suit-that-attempted-to-stop-medicare-subsidy-cuts-1514591994>.
- 2018
 - Firth, Shannon. “Industry Experts, Clinicians Seek Solutions to Drug Shortages”. *Medpage Today*. Nov. 28, 2018. *Available at*:
<https://www.medpagetoday.com/publichealthpolicy/fdageneral/76575>.
 - Reprinted by *Health Leaders*. Nov. 29, 2018. *Available at*:
<https://www.healthleadersmedia.com/clinical-care/industry-experts-clinicians-look-for-solutions-to-drug-shortages>.
 - Luhby, Tami & Fox, Lauren. “Trump leans into midterms with a pitch to un-rig Medicare drug prices”. *CNN*. Oct. 25, 2018. *Available at*:
<https://www.cnn.com/2018/10/25/politics/trump-drug-prices/index.html>.
 - Scott, Dylan. “The exciting new idea hospitals have to bring down drug prices”. *Vox*. Oct. 8, 2018. *Available at*: <https://www.vox.com/policy-and-politics/2018/10/8/17952702/hospital-down-drug-prices>.

- Tribble, Sarah J. “Trump Administration Sinks Teeth into Paring Down Drug Prices, On 5 Key Points”. *Kaiser Health News*. Aug. 10, 2018. *Available at:* <https://khn.org/news/with-5-point-plan-trump-administration-sinks-teeth-into-paring-down-drug-prices/>.
 - Reprinted by *The Washington Post*. Aug. 10, 2018. *Available at:* https://www.washingtonpost.com/national/health-science/trump-administration-sinks-teeth-into-paring-down-drug-prices-on-5-key-points/2018/08/10/4ed5e18a-9c84-11e8-a8d8-9b4c13286d6b_story.html.
- Sullivan, Thomas. “GAO Report Highlights 340B Contracting Practices”. *Policy & Medicine*. July 8, 2018. *Available at:* <https://www.policymed.com/2018/07/gao-report-highlights-340b-contracting-practices.html>.
- Karlin-Smith, Sarah. “Prescription Pulse: Perverse incentives? Why some 340B pharmacies are opting for branded drugs”. *Politico*. July 2, 2018. *Available at:* <https://www.politico.com/newsletters/prescription-pulse/2018/07/02/perverse-incentives-why-some-340b-pharmacies-are-opting-for-branded-drugs-268802>.
- Tozzi, John & Ockerman, Emma. “Drug Prices Drive Many Americans to Black Market for Medicines”. *Bloomberg*. May 18, 2018. *Available at:* <https://www.bloomberg.com/news/articles/2018-05-18/drug-prices-drive-many-americans-to-black-market-for-medicines>.
- Scott, Dylan. “The 6 most interesting parts of Trump’s mostly disappointing drug price plan”. *Vox*. May 11, 2018. *Available at:* <https://www.vox.com/policy-and-politics/2018/5/11/17346436/trump-speech-prescription-drug-costs-medicare>.
- “Issue No. 30: A Day of Reckoning Approaches for 340B, the Controversial Drug Pricing Programs”. *Cost of Health Care News*. May 8, 2018. *Available at:* <http://www.cost-of-health-carenews.com/our-blog/issue-no-30-a-day-of-reckoning-approaches-for-340b-the-controversial-drug-pricing-programs>.
- “Why 'medical charities' are so controversial”. *Advisory Board*. May 7, 2018. *Available at:* <https://www.advisory.com/daily-briefing/2018/05/07/medical-charities>.

- Johnson, Carolyn Y. & Ribas, Jorge. “Mother, wife, million-dollar patient”. *The Washington Post*. April 25, 2018. *Available at:*
<https://www.washingtonpost.com/graphics/2018/business/million-dollar-patient/>.
 - Reprinted by *Stamford Advocate*. April 25, 2018. *Available at:*
<https://www.stamfordadvocate.com/news/article/Mother-wife-million-dollar-patient-Keeping-her-12863985.php>
- Hernandez, Randi. “Lawmakers demand details on 1,400% price hike for cancer drug”. *Biopharma Dive*. April 4, 2018. *Available at:*
<https://www.biopharmadive.com/news/lawmakers-demand-details-on-1400-price-hike-for-cancer-drug/520613/>.
- Conti, Rena. “340B Drug Discount Program: Why More Transparency Will Help Low-Income Communities”. *The Point*. Mar. 15, 2018. *Available at:*
<http://www.longtermcarescorecard.org/publications/blog/2018/mar/340b-drug-discount-program>.
- Sanborn, Beth J. “Intermountain-led generic drug venture faces big hurdles, could forge new regulatory and political ground”. *Healthcare Finance*. Mar. 15, 2018. *Available at:* <https://www.healthcarefinancenews.com/news/intermountain-led-generic-drug-venture-faces-big-hurdles-could-forge-new-regulatory-and>.
- Howard, Jacqueline. “Cancer treatment guidelines questioned in new study”. *CNN*. Mar. 8, 2018. *Available at:* <https://www.cnn.com/2018/03/07/health/cancer-treatment-guidelines-study/index.html>.
- Johnson, Carolyn Y. “UnitedHealthcare will provide drug rebates directly to members in some plans”. *The Washington Post*. Mar. 6, 2018. *Available at:*
<https://www.washingtonpost.com/news/wonk/wp/2018/03/06/unitedhealthcare-will-provide-drug-rebates-directly-to-members-in-some-plans/>.
- Nelson, Roxanne. “Hospitals, Not Poor Patients, Gain From 340B Program”. *Medscape Medical News*. Jan. 29, 2018. *Available at:*
https://www.medscape.com/viewarticle/891908#vp_1.

- Brennan, Zachary. “Drugmakers Weigh CMS Plan to Apply Rebates and Price Concessions at Point of Sale”. *Regulatory Focus*. Jan. 23, 2018. Available at: <https://www.raps.org/news-and-articles/news-articles/2018/1/drugmakers-weigh-cms-plan-to-apply-rebates-and-pri>.
- “Reimbursement for oncology biosimilars in the US”. *Generics and Biosimilars Initiative*. Jan. 5, 2018. Available at: <http://gabionline.net/Biosimilars/Research/Reimbursement-for-oncology-biosimilars-in-the-US>.
- Minemyer, Paige. “Judge dismisses suit over 340B cuts; hospital groups vow to continue legal fight”. *Fierce Healthcare*. Jan. 2, 2018. Available at: <https://www.fiercehealthcare.com/finance/340b-drug-discount-program-cuts-american-hospital-association-lawsuit-dismissed>.
- 2019
 - WSJ: Louisiana’s Deal for Hepatitis C Drugs May Serve as Model
 - Also appears in Dow Jones Institutional News (according to Factiva)
 - Brookings: Louisiana’s innovative drug purchasing program, and what it could mean for the country
 - Salon: Here's why the bipartisan push to lower drug prices never works
 - Appears on both national level and WBUR
 - Politico: Prescription Pulse: Trump drug pricing agenda dramatically shrinks
 - Medical Daily: Louisiana’s Subscription Model For Hep C Drugs: What You Need To Know
 - Digest of NPR article
 - NPR: Louisiana's Novel 'Subscription' Model For Pricey Hepatitis C Drugs Gains Approval
 - Appears on both national level and 89.9 of NOLA (and other stations, saw WAMU 88.5 too, and I anticipate others ran the story)
 - Science Daily: Reforming pharmacy benefit manager practices may lead to drug cost savings
 - Wash Post: Low prices of some lifesaving drugs make them impossible to get

- Cost of Health Care News: Issue No. 46: Where the Cost Savings Are: Hospitals
- Cited in: House Energy and Commerce Subcommittee on Health Hearing; "Improving Drug Pricing Transparency and Lowering Prices for American Consumers."; Testimony by Frederick Isasi, Executive Director, Families USA; WAX52052119H006
- U Mich Institute for Healthcare Policy & Innovation: Opioid doctor and pharmacy “shoppers” may also shop at home, study suggests
- WBUR: \$2 Million Drug? Treatment For Rare Genetic Disease Is Expected To Break Price Record
- AARP Español: Un plan de cinco puntos para reducir los precios de los medicamentos recetados
- Barrell, Amanda. “Measuring value to ensure access in divisive times”. *Pharma Phorum*. Oct. 31, 2019. Available at: <https://pharmaphorum.com/views-analysis-market-access/measuring-value-to-ensure-access-in-divisive-times/>.
- “Issue No. 54: How to Fulfill the Promise of Biosimilars”. *Cost of Health Care News*. Oct. 29, 2019. Available at: <http://www.cost-of-health-carenews.com/our-blog/issue-no-54-how-to-fulfill-the-promise-of-biosimilars>.
- Conti, Rena. “Determining drug value: Let’s start with the evidence”. *Kaiser Permanente Institute for Health Policy*. Oct. 24, 2019. Available at: <https://www.kpihp.org/blog/determining-drug-value-lets-start-with-the-evidence/>.
- Tarlo, Shira. “California's drug pricing transparency law reveals stunning increases in wholesale prices”. *Salon*. Oct. 20, 2019. Available at: <https://www.salon.com/2019/10/20/californias-drug-pricing-transparency-law-reveals-stunning-increases-in-wholesale-prices/>.
- Karlin-Smith, Sarah & Owerrohle, Sarah. “Prescription Pulse: Trump roars at pharma in speech ... but his policy bleats”. *Politico*. Oct. 4, 2019. Available at: <https://www.politico.com/newsletters/prescription-pulse/2019/10/04/trump-roars-at-pharma-in-speech-but-his-policy-bleats-485311>.

- Owermhle, Sarah. “Prescription Pulse: Do big box pharmacies have better generic prices?”. *Politico*. Oct. 1, 2019. *Available at:*
<https://www.politico.com/newsletters/prescription-pulse/2019/10/01/do-big-box-pharmacies-have-better-generic-prices-483782>.
- Goldman, Dana. “Who Would Have Believed it? Markets Can Reduce the ‘True’ Price of Cancer Drugs”. *The Evidence Base*. Sept. 28, 2019. *Available at:*
<https://healthpolicy.usc.edu/evidence-base/who-would-have-believed-it-markets-can-reduce-the-true%E2%80%8B-price-of-cancer-drugs/>.
- Frieden, Joyce. “Louisiana Signs Up for 'Subscription' to Hep C Treatment”. *Medpage Today*. Aug. 12, 2019. *Available at:*
<https://www.medpagetoday.com/infectiousdisease/hepatitis/81557>.
 - Reprinted by *Health Leaders*. Aug. 13, 2019. *Available at:*
<https://www.healthleadersmedia.com/louisiana-signs-subscription-hep-c-treatment>.
- Jones, Sarah. “Another Person Has Died After Rationing Insulin”. *New York Magazine: Intelligencer*. July 15, 2019. *Available at:*
<http://nymag.com/intelligencer/2019/07/another-person-has-died-from-rationing-insulin.html>.
- Owermhle, Sarah. “Prescription Pulse: Trump drug pricing agenda dramatically shrinks”. *Politico*. July 12, 2019. *Available at:*
<https://www.politico.com/newsletters/prescription-pulse/2019/07/12/trump-drug-pricing-agenda-dramatically-shrinks-456451>.
- Owermhle, Sarah. “Prescription Pulse: Oklahoma portrays J&J as opioid crisis 'kingpin' in court battle”. *Politico*. July 3, 2019. *Available at:*
<https://www.politico.com/newsletters/prescription-pulse/2019/07/03/oklahoma-portrays-j-j-as-opioid-crisis-kingpin-in-court-battle-453721>.
- Gavin, Kara. “Opioid doctor and pharmacy ‘shoppers’ may also shop at home, U-M study suggests”. *University of Michigan Communications*. May 10, 2019.
Available at: <https://news.umich.edu/opioid-doctor-and-pharmacy-shoppers-may-also-shop-at-home-u-m-study-suggests/>.

- Silverman, Ed. “If the states don’t treat pharma as a utility, it may be ‘lights out’ for too many patients”. *STAT*. April 25, 2019. *Available at:* <https://www.statnews.com/2019/04/25/states-pharma-utility-price-caps-patients/>.
- Court, Emma. “Meet the little-known Harvard spinoff that’s standing up to Big Pharma and setting its own price tags for new drugs”. *Business Insider*. April 16, 2019. *Available at:* <https://www.businessinsider.com/icer-nonprofit-harvard-targeting-high-us-drug-prices-led-by-steven-pearson-2019-4>.
- Owens, Caitlin. “The drug pricing debate is stuck in the past”. *Axios*. Mar. 29, 2019. *Available at:* <https://www.axios.com/drug-pricing-debate-stuck-in-past-10ba315e-0ddf-4013-8c5a-f8ee89c2f530.html>.
- “Louisiana One Step Closer to Breakthrough Approach in Hepatitis C Treatment”. *Arnold Ventures*. Mar. 2, 2019. *Available at:* <https://www.arnoldventures.org/stories/louisiana-one-step-closer-to-breakthrough-approach-in-hepatitis-c-treatment/>.
- Swetlitz, Ike. “Hospitals are saving lives with CAR-T. Getting paid is another story”. *STAT*. Mar. 12, 2019. *Available at:* <https://www.statnews.com/2019/03/12/hospitals-arent-getting-paid-for-car-t/>.
- Kelly, Cathy. “Price ‘Anchoring’? Zolgensma And The Art Of Managing Gene Therapy Sticker Shock”. *PharmaIntelligence*. Feb. 19, 2019. *Available at:* <https://pharmaintelligence.informa.com/resources/product-content/price-anchoring-zolgensma-and-the-art-of-managing-gene-therapy-sticker-shock>.
- Lupkin, Sydney & Hancock, Jay. “Trump Administration Salutes Parade of Generic Drug Approvals, But Hundreds Aren’t for Sale”. *Kaiser Health News*. Feb. 7, 2019. *Available at:* <https://khn.org/news/trump-administration-salutes-parade-of-generic-drug-approvals-but-hundreds-arent-for-sale/>.
 - Reprinted by *CNN*. *Available at:* <https://www.cnn.com/2019/02/07/health/trump-generic-drug-approvals-partner/index.html>.

- Reprinted by *The Fiscal Times*. Available at:
<https://www.thefiscaltimes.com/2019/02/08/Record-Approvals-Generic-Drugs-Many-Aren-t-Sale>.
- Reprinted by *The Tampa Bay Times*. Available at:
<https://www.tampabay.com/health/the-fda-under-trump-has-approved-1600-generic-drugs-but-many-arent-for-sale-yet-20190208/>.
- “Issue No. 39: Where Are Health Costs Rising Most? Hospitals. And Here is Why.” *Cost of Health Care News*. Feb. 4, 2019. Available at: <http://www.cost-of-health-carenews.com/our-blog/issue-no-39-where-are-health-costs-rising-mosthospitals-and-here-is-why>.
- Linna, Su. “The Warren bill could promote beneficial public-private partnerships in life sciences”. *STAT*. Jan. 21, 2019. Available at:
<https://www.statnews.com/2019/01/21/warren-bill-promote-public-private-partnerships/>.
- Loftus, Peter. “Drugmakers Raise Prices Amid Shortages, Recalls”. *The Wall Street Journal*. Jan. 18, 2019. Available at:
<https://www.wsj.com/articles/drugmakers-raise-prices-amid-shortages-recalls-11547807400>.
- Fordham, Evie. “Drug Companies Used Shortages, Recalls To Hike Prices As Much As 1,137 Percent, Report Finds”. *Daily Caller*. Jan. 18, 2019. Available at:
<https://dailycaller.com/2019/01/18/drug-companies-price-increases/>.
- Johnson, Steven R. “340B hospitals breathing easier under Dem-controlled House”. *Modern Healthcare*. Jan. 12, 2019. Available at:
<https://www.modernhealthcare.com/article/20190112/NEWS/190119982/340b-hospitals-breathing-easier-under-dem-controlled-house>.

- Stanley, Tiffany. “Life, Death and Insulin”. *The Washington Post Magazine*. Jan. 7, 2019. Available at: <https://www.washingtonpost.com/news/magazine/wp/2019/01/07/feature/insulin-is-a-lifesaving-drug-but-it-has-become-intolerably-expensive-and-the-consequences-can-be-tragic/>.
 - Reprinted by *The Salt Lake Tribune*. Jan. 8, 2019. Available at: <https://www.sltrib.com/news/nation-world/2019/01/08/skyrocketing-cost-insulin/>.
 - Reprinted by *The Twin Cities Pioneer Press*. Jan. 9, 2019. Available at: <https://www.twincities.com/2019/01/09/insulin-cost-prescription-drugs-diabetes-insurance/>.
 - Reprinted by *The Daily Chronicle*. Jan. 10, 2019. Available at: <https://www.daily-chronicle.com/2019/01/10/skyrocketing-cost-of-insulin-causes-some-desperate-diabetics-to-ration/a40mowy/>.
- 2020:
 - Holden E. ‘US prescription drug supply chains are vulnerable to coronavirus. ‘US prescription drug supply chains face coronavirus stress test’. *The Guardian*, March 17 2020, Available online at: <https://www.theguardian.com/world/2020/mar/17/us-prescription-drug-supply-chains-coronavirus>
 - Kirby Jen ‘Could the coronavirus spark drug shortages in the US?’ *Vox*, March 9 2020, Available online at: <https://www.vox.com/2020/3/9/21163356/coronavirus-drug-shortage-potential-fda-china-india>
 - Pearl M, ‘Can you get a coronavirus test without going broke?’ *Vice news*, March 13 2020, Available online at: <https://www.thedailybeast.com/can-you-get-a-coronavirus-test-without-going-broke>
 - Herz M. ‘Could the coronavirus affect the drug supply in the US?’. *WGBH news*, January 29 2020, Available online at: <https://www.wgbh.org/news/local-news/2020/01/29/could-the-coronavirus-affect-the-drug-supply-in-the-us>
 - Pearl M, ‘How Not to Be a Coronavirus Jerk’. *Vice news*, March 17 2020, Available online at” https://www.vice.com/en_us/article/pkewey/how-not-to-be-a-coronavirus-jerk

- Mitchell D, ‘COVID-19 TREATMENTS WON’T WORK IF WE CAN’T AFFORD THEM.’ Patients for Affordable Drugs Blog, March 26 2020, Available online at: <https://www.patientsforaffordabledrugs.org/2020/03/26/covid-19/>

A.7. Honors, prizes, and awards

- US Bureau of Labor Statistics, Price Index Research Division, Predoctoral Fellowship, Washington, DC, 2003–2004.
- National Institutes of Mental Health, Ruth L. Kirschstein Individual Predoctoral Fellowship, Cambridge, MA, 2004–2005.
- Alan Williams Fellowship in Health Economics, University of York, UK, 2007.
- Questrom School of Business, Angela M. Noe Faculty Research Fund, 2019.
- Questrom School of Business, Dean’s Research Scholar, 2019-2022.

A.8. Invited speaking (selected, not comprehensive)

A.8.a. Extramural: Peer-review selected

- Previous to 2017
 - “The Effect of FDA Advisories on Branded Pharmaceutical Firms.”
 - Pharmaceutical Economics and Policy Conference, Miami, FL, May 2011.
 - International Health Economics Association, Annual Meeting, Toronto, CA, July 2011.
 - American Health Economics Association Annual Meeting, Minneapolis, MN, July 2012.
 - “The Discovery, Financing and Evaluation of Genomic Medicine: Implications for Cancer Care,” Annual Society for Medical Decision Making, Organized Saturday Symposium, Toronto, Canada, October 2011.
 - “Anatomy of US Cancer Drug Shortages.”
 - Global Health Economics Forum, Amsterdam, NE, June 2012.
 - National Bureau of Economic Research, Industrial Organization Seminar, Cambridge, MA, February 2013.

- Petrie Flom Center, Harvard Law School, Law and Economics Conference on the FDA, Cambridge, MA, May 2013.
- Industry Studies Conference, Supply Chain Response: Dealing with Disruption, Shortages, and Uncertainty, Kansas City, MO, June 2013.
- Massachusetts Institute of Technology, Sloan School of Business, micro@sloan Conference, Cambridge, MA, August 2013.
- “Are New Drugs More Expensive than Old Ones? Trends in the Benefit-Adjusted Launch Prices of Anticancer Drugs, 1995–2013,” 2014 American Society of Clinical Oncology Annual Meeting, May 2014; Abstract published in *Journal of Clinical Oncology* 2014:32:5s (suppl; abstr 6525).
- “The Intended and Unintended Consequences of 340B Program Expansions,” Bates White Life Sciences Symposium, Washington, DC, June 2014.
- “Specialty Drug Prices and Utilization after Loss of US Patent Exclusivity, 2001–2007.”
 - American Society of Health Care Economists, LA, CA. June 2014.
 - International Health Economics Association, Annual Meeting, Podium presentation, Economics of Pharmaceuticals, Milan, Italy, July 2015.
- “The Economic Causes and Consequences of US Drug Shortages” (with ER Berndt), American Society of Health Care Economists, LA, CA, June 2014. Program available: <https://ashecon.confex.com/ashecon/2014/webprogram/Session1339.html>.
- “Who Makes This Drug? Challenges in Assessing Biopharmaceutical Industry Structure and Conduct,” Society for Economic Measurement Annual Meeting, Chicago, IL, August 2014.
- “Estimating the Cost-Effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase Following Imatinib’s Generic Entry in the US.”
 - 16th Annual John Goldman Conference, Philadelphia, PA, September 2014.
 - American Society of Hematologists Annual Meeting, San Francisco, CA, December 2014.

- International Health Economics Association, Annual Meeting, Podium Presentation, Economics of Cancer, Milan, Italy, July 2015.
- “The ACA’s Effect on Outpatient Medical Practice Consolidation: Likely Price and Quality Outcomes,” ACA Policy Diffusion Project, Robert Wood Johnson Foundation Conference: Diffusion of ACA Policies across the American states: What? How? Why? Chicago, IL, June 2015.
- “A Tale of Two (Drug) Prices.”
 - Society for Economic Measurement Annual Meeting, Paris, France, July 2015.
 - Ashecon, J Philadelphia, PA, June 2016.
- “The Impact of Provider Consolidation on Outpatient Cancer Care Prices.”
 - National Academy for State Health Policy Annual Conference, Dallas, TX, October 2015.
 - Healthcare Markets Conference, Kellogg School of Management, Northwestern University, Evanston, IL, April 2016.
 - Ashecon, Philadelphia, PA, June 2016.
- “Provider Consolidation and Outpatient Cancer Care Prices,” National Academy for State Health Policy Webinar, December 2015.
 - “Patient Medication Adherence among HIV/AIDS Patients Receiving 340B-Purchased Antiretroviral Medications,” International Society for Pharmacoeconomics and Outcomes Research, Washington, DC, May 2016.
- “Drug Prices: Follow the Money—How Costs and Payments Impact Diabetes Care,” American Diabetes Association, Annual Meeting, Scientific Sessions, New Orleans, LA, June 2016.
- “The Economics of Drug Shortages,” Organized Session, Ashecon, Philadelphia, PA, June 2016.
- “Medication Adherence among 340B Patients with Hypertension, Hyperlipidemia, and Diabetes,” Academy Health Annual Meeting, Boston, MA, June 2016.

- “Generic Drug Prices Rise Worldwide, Why?” Society for Economic Measurement annual meeting, Thessolonki, Greece, July 2016.
- 2017
 - “GDUFA Reauthorization: Economic Perspective,” Bates White Life Sciences Symposium, Washington, DC, May 2017.
 - “Hot Spots and Bad Actors: Prescription Drug Price Trends 2012–2014.”
 - IMS Health Institute Research Forum, Boston, MA, May 2017.
 - Academy Health Annual Meeting, New Orleans, LA, June 2017.
- 2018
 - “Prices of and Spending on Outpatient Prescription Drug-Based Cancer Care after Physician Consolidation with Health Systems,” Allied Social Sciences Association, Philadelphia, PA, January 2018.
 - “The Landscape of US Generic Prescription Drug Markets, 2004–2016,” Organized Session, Ashecon, Atlanta, GA, June 2018.
- 2019
 - Facts Concerning Competition in Generic Drug Markets, Ashecon, Washington, DC, June 2019
 - The Incidence of Hospital Drug Price Subsidies: 340B, Drug Utilization, and Subsidized Medical Care, Ashecon, Washington, DC, June 2019
 - How Competitive Are U.S. Generic Prescription Drug Markets 2009-2016? Society for Economic Measurement annual meeting, Germany, August 2019
 - The Changing Geography of Prescription Pharmaceutical Supply: Levels, Trends and Implications, Society for Economic Measurement annual meeting, Germany, August 2019
 - Panelist, Improving Value in Healthcare, APPAM, Denver, Colorado, November 2019
 - Discussant, Policy Determinants of Prescription Drug Use, APPAM, Denver, Colorado, November 2019

- How Competitive Are U.S. Generic Prescription Drug Markets 2009-2016?, Emerging Evidence to Inform Medicare Prescription Drug Policy, APPAM, Denver, Colorado, November 2019

A.8.b. Extramural: Invited (selected, not comprehensive)

- Previous to 2017
 - “The Effect of FDA Advisories on Branded Pharmaceutical Firms.”
 - United States Food and Drug Administration, Washington, DC, May 2011.
 - DePaul University, Economics Department, Chicago, IL, October 2011.
 - “The Economics of Comparative Effectiveness Studies: Societal and Private Perspectives and Their Implications for Prioritizing Public Investments in Comparative Effectiveness Research,” Decide Network Health Economics Seminar, Chicago, IL, May 2011.
 - “Antidepressant Treatment and Suicide Attempts in Children and Adolescents,” Columbia University, School of Public Health, Department of Health Policy and Management, New York, June 2011.
 - “Infused Chemotherapy Use Following Patent Expiration among Individuals Aged 65 and Older,” Chicago Council of Science and Technology Symposium, Chicago, IL, November 2011.
 - “The Economic, Legal and Scientific Implications of Gene Patents,” Chicago Council of Science and Technology Symposium, Chicago, IL, November 2011.
 - “Anatomy of US Cancer Drug Shortages.”
 - Massachusetts Institute of Technology, Sloan School of Management, Cambridge, MA, May 2012.
 - Massachusetts Institute of Technology, Sloan School of Management, Cambridge, MA, April 2013.
 - United States Government Accountability Office, Washington, DC, June 2013.
 - United States Bureau of Economic Analysis, Washington, DC, November 2013.

- “Show Me the Money: Reimbursement in an ACA World,” 2014 BIO International Convention, New York, February 2013. Webcast available: <https://www.youtube.com/watch?v=j6Cezq22woI>.
- “The Intended and Unintended Consequences of 340B Program Expansions.”
 - 2013 Bio International Convention, Payer Reimbursement and Drug Shortages Sessions, Chicago, IL, April 2013.
 - Institute of Medicine, National Cancer Policy Forum Workshop. Ensuring Patient Access to Cancer Drugs, Washington, DC, June 2014. Webcast available: <https://www.iom.edu/Activities/Disease/NCPF/2014-JUN-09.aspx>.
- “Economic Issues Underlying Recent Drug Shortages in the US,” 2013 Bio International Convention, Payer Reimbursement and Drug Shortages Sessions, Chicago, IL, April 2013.
- “The Financing and Organization of Rare Disease Pharmacotherapy,” Genzyme, Global Health Policy Symposium, Approaches to Value and Modeling in Rare Diseases, Cambridge, MA, May 2013.
- “Trends and Determinants of Novel Anti-Cancer Drug Launch Prices in the United States,” University of North Carolina Chapel Hill, Health Policy and Management, Chapel Hill, NC, December 2013.
- “Specialty Drug Prices and Utilization after Loss of US Patent Exclusivity, 2001–2007.”
 - Pfizer Health Economics Seminar, New York, May 2014.
 - Health Economics Workshop, Emory University Rollins School of Public Health, Atlanta, Georgia, May 2015.
- “Bending the Cost Curve in Cancer Treatment: The ACA and Beyond.”
 - ASCO Annual Meeting, Chicago, IL, May 2014.
 - Best of ASCO Annual Meeting, Seattle, Washington, August 2014.
- “Pricing in the Market for Anticancer Drugs,” NCI and Accenture Strategic Panel on Life Science Innovation. Chicago, IL, May 2014.
- “Specialty Drug Spending,” Accenture Life Sciences Annual Meeting, Washington, DC, October 2014.

- “National Trends in Spending on and Use of Oral Oncologics, 2006–2011,” Health Affairs Briefing: Specialty Pharmaceuticals, October 2014.
- “The 340B Drug Discount Program: Hospitals Generate Profits by Expanding to Reach More Affluent Communities,” Health Affairs Briefing: Specialty Pharmaceuticals, October 2014.
- “Pricing in the Market for Anticancer Drugs.”
 - MIT Sloan School of Business CANCER Rx Conference, Boston, MA, October 2014.
 - Health Economics Seminar, University of Iowa, Department of Economics, November 2014.
 - UCLA Seminar on Pharmaceutical Economics and Policy, Los Angeles, CA, December 2014.
 - University of Illinois Chicago, Pharmacy Systems, Outcomes and Policy lunchtime seminar, Chicago, IL. January 2015.
- “Access to and Value of Treatment Innovation in Blood Cancers,” American Cancer Society CRP Cancer Care Delivery Research Committee, Chicago, IL, November 2014.
- “Ebola-Economics—The Cost of Health Crisis: Measuring the Economic and Human Toll of Pandemics,” Illinois Humanities Council, Chicago, IL. January 2015. Webcast available: <http://cantv.org/watch-now/the-cost-of-health-crisis-measuring-the-economic-and-human-toll-of-pandemics/>.
- “Bending Medicare’s Cost Curve in Cancer Care,” Grand Rounds Invited Speaker, Winship Cancer Institute, of Emory University, Atlanta, Georgia, May 2015.
- “Health Economist’s View of Value-Based Care,” ASCO Annual Meeting, “Alternatives to ASP-Plus-Six: What Are the Options?” Chicago, IL, May 2015.
- “Changing the Incentives for Specialty Drug Development,” Keynote Speaker, Sachs Immuno-Oncology: BD&L and Investment Forum, Chicago, IL, May 2015.

- “Criteria Needed to Be Implemented before Making Innovative Drug Pricing a Reality,” NCI and Accenture Strategic Panel on Life Science Innovation. Chicago, IL, May 2015.
- “Pricing for Value: Specialty Drugs: Paying for Value: Policy Options for Managing the Cost of PCSK9 Inhibitors and Other Specialty Drugs,” Pew Charitable Trusts, Washington, DC, October 2015.
- “Generic Drug Prices Rise, Why?” US Senate Health Education Labor and Pensions Subcommittee, health policy staff conference, Washington, DC, January 2016.
- “Cancer Drugs: The Economics of Access and Affordability.”
 - The Leukemia & Lymphoma Society, Thought Leadership Roundtable, “Blood Cancers: Standards of Care, Gateways to Cancer Cures,” Invited panelist, February 2016.
 - University School of Medicine, Department of Health Policy, “Special Lecture Series on Value in Oncology Care,” Invited panelist, March 2016.
- “The ACA’s Effect on Oncology Practice Consolidation: The Prices of Outpatient Cancer Treatments,” Invited talk for the Robert Wood Johnson Health Policy Scholars, University of Michigan, Ann Arbor, MI, April 2016.
- “The Impact of Provider Consolidation on Outpatient Cancer Care Prices,” Johns Hopkins University School of Public Health, Baltimore, MD, April 2016.
- “The Economics of Specialty Drug Spending: Opportunities for Reform.”
 - American Medical Association, Leadership Policy Committee, Chicago, IL, June 2016.
 - Invited workshop, Senator Bill Cassidy and Health Policy Staff, Washington, DC, July 2016.
 - Invited workshop, Senator Al Franken and Health Policy Staff, Washington, DC, July 2016.
 - Manhattan Institute, New York, November 2016.
- “Drug Prices: Value, Affordability, and Advocacy,” Invited Panelist, Doctors for America Webinar June 2016.

- “The Economics of Specialty Drug Spending: Opportunities for Reform and Research,” University of Colorado, Department of Medicine, Denver, CO, July 2016.
- “Prescription Drug Prices: The Promises and Perils of Alternative Payment Models,” Leadership Consortium for a Value & Science-Driven Health System, National Academy of Medicine, September 2016.
- Discussion comments on “Pass-Through in a Highly Regulated Supply Chain,” 27th Annual Health Economics Conference, Vanderbilt University, Nashville, TN, October 2016.
 - “Financing the Safety Net: Now and in the Future,” University of Kansas Medical Center, Medical Care Executive Training Program, Kansas City, KS, November 2016.
- “The Prices of Outpatient Prescription Drug-Based Cancer Care after Physician Consolidation with Health Systems,” University of Kansas Medical Center, Health Policy Research Group, presentation followed by panel discussion, Kansas City, KS, November 2016.
- “The Economics of Medical Practice Consolidation,” Large Urology Group Practice Association Annual Meeting, Chicago, IL, November 2016.
- 2017
 - “Ensuring Access to HIV & Hepatitis C Treatment: Economic Challenges and Opportunities,” President’s Advisory Commission on HIV/AIDs, Washington, DC, March 2017.
 - “High Prescription Drug Prices: Causes, Consequences, Reform Opportunities.”
 - Columbia University School of Public Health and Comprehensive Cancer Center, New York, April 2017.
 - Altarum Center for Sustainable Health Spending Presents: Beyond the ACA: Health Policy and Sustainable Health Spending, Washington, DC, July 2017.
 - “High Prescription Drug Prices: What Should Employers Do to Curb Spending?” National Business Group on Health Roundtable Discussion, Washington, DC, April 2017.

- “Price Estimates for HCV Prescription Drug-Based Treatments under 1498,” Hepatitis C Treatment and Section 1498 Meeting, Webcast. Johns Hopkins University School of Public Health, Baltimore, MD, April 2017.
- “Consumer Learning and the Entry of Generic Pharmaceuticals,” Discussant, Midwest Health Economics Conference, Minneapolis, MN, May 2017.
- “Cancer Economics in the Trump Years,” ASCO Annual Meeting, Chicago, IL, June 2017.
- “Prescription Drug Reimbursement Opportunities and Challenges in 2017–2018,” Sachs Associates: Immuno-oncology Investor Forum, Chicago, IL, June 2017.
- “Value Assessments Are a Necessary, Not Sufficient Condition to Ensure Access to New Prescription Drugs,” Health Affairs/Project Hope Policy Forum: Understanding the Value of Innovations in Medicine, Washington, DC, September 2017.
- “High Prescription Drug Prices: Balancing Access and Affordability,” Washington State Medical Oncology Society, Seattle, WA, October 2017.
- 2018
 - Tuesday Plenary: Economics and the Drug Pricing Debate, Ashecon, Atlanta, GA, June 2018.
 - Medical Product Shortages during Disasters: Opportunities to Predict, Prevent, and Respond: A Workshop, National Academy of Medicine, September 2018.
 - The Cost of a Cure: Creating Sustainable Solutions for Gene and Cell Therapies. Leonard Davis Institute, University of Pennsylvania, September 2018
- 2019
 - How Competitive Are U.S. Generic Prescription Drug Markets, 2009-2016, UCLA, Pharmaceutical Economics and Policy Seminar, April 2019
 - Panelist, Drug Pricing Reform, Alliance for Health Policy Senate Health Care Retreat, Virginia, April 2019
 - How Competitive Are U.S. Generic Prescription Drug Markets, 2009-2016, BU Law School, May 2019

- Where are we going on Drug Pricing? Keynote, Tufts Center for Economic Value Research Annual Meeting, Boston June 2019
- Discussant, Safety Net Cutbacks and Hospital Service Provision: Evidence from Psychiatric Care, Ashecon, Washington, DC, June 2019
- Discussant, Effects of Pharmaceutical Patents on Patient Welfare: Evidence from Generic Entry of Oral Breast Cancer Therapies, Ashecon, Washington, DC, June 2019
- Monday Plenary: The Future of Drug Pricing, Ashecon, Washington, DC June 2019
- Altarum: Altarum's Ninth Annual Sustainable Health Care Spending Symposium, June 2019
- The Hill: Future of Healthcare Summit, Washington, DC, June 2019
- Pricing for innovative therapies, Analysis Group: Law & Economics Symposium, June 2019
- Panelist, Brookings Institute: Louisiana's prescription drug experiment: A model for the nation? July 2019
 - Brookings write-up: <https://www.nifusa.org/panel-report-netflix-model-for-pharmaceuticals-at-brookings/>
- Q1 Productions: 4th Annual Pharmaceutical Strategic Pricing Conference, Philadelphia September 2019
- Panelist, Defining and Assessing Drug Value Kaiser Permanente's Institute for Health Policy forum, *Unpacking Drug Value: A Path to Fair Pricing*, Washington, DC September 2019
- Panelist, Exploring the Value and Cost-Effectiveness of CAR T-cell Therapy, AACI, Washington, DC, October 2019
- Panelist, The Atlantic: Future of Healthcare Summit, Washington, DC, October 2019
- Pricing for innovative therapies. Innovative Genomics Institute and Center to Advance Science in Policy & Regulation Joint Seminar, University of California - Berkeley, October 2019

- Challenges to the domestic supply of generic drugs. Research Day, IQVIA Boston, October 2019
- The domestic supply of off-patent prescription drugs. Second Annual Intellectual Property & Innovation Conference, Suffolk Law School, Boston, October 2019

A.9. Intramural speaking (selected, not comprehensive)

- University of Chicago
 - Previous to 2017
 - “How Do Initial Signals of Quality Influence the Diffusion of New Medical Products? The Case of New Cancer Treatments,” The University of Chicago, Section of Hematology/Oncology, Research Seminar Series, April 2011.
 - “Infused Chemotherapy Use Following Patent Expiration among Individuals Aged 65 and Older,” The University of Chicago, Health Economics Workshop, May 2011.
 - “The Effect of FDA Advisories on Branded Pharmaceutical Firms,” The University of Chicago, Health Economics Workshop, October 2011.
 - “The Impact of FDA Regulatory Actions on Bevacizumab Use for Breast Cancer,” The University of Chicago, Cancer Economics Lunchtime Seminar, April 2012.
 - “The Prevalence of On-Label Use of Patent Protected Anti-Cancer Drugs,” The University of Chicago, Health Economics Workshop, April 2012.
 - “Anatomy of US Cancer Drug Shortages.”
 - Cancer Economics Lunchtime Seminar, November 2012.
 - Cancer Economics Lunchtime Seminar, March 2013.
 - “Trends and Determinants of Novel Anti-Cancer Drug Launch Prices in the United States,” The University of Chicago, Health Economics Workshop, April 2013.
 - “Bending the Cost Curve in Cancer Treatment: The ACA and Beyond,” Health reform: Maclean Center Seminar Series, February 2014.
 - “Specialty Drug Prices and Utilization after Loss of US Patent Exclusivity, 2001–2007,” Cancer Economics Lunchtime Seminar, March 2014.

- “Pricing in the Market for Anticancer Drugs,” 2014 Symposium on Pharmaceutical Policy and Vulnerable Populations, September 2014.
- “Cures for High and Growing Spending on Pharmaceuticals,” Grand Rounds, Pritzker School of Medicine, August 2015.
- “The Economics and Financing of Prescription Drug Supply Chains,” Annual Healthcare Conference moderator, Booth School of Business, October 2015.
- “The Impact of Provider Consolidation on Outpatient Cancer Care Prices,” Cancer Health Policy Seminar, December 2015.
- Panelist, “Government Regulation in Pharmaceutical Pricing: Too Much or Too Little?” Chicago Booth’s 15th Annual Healthcare Conference, November 2016.
- Panelist, “What’s Next for Obamacare? The Future of Insurance Coverage and Healthcare,” Booth Health Care Group and the Graduate Program in Health Administration and Policy, December 2016.
- 2017
 - Panelist, “What’s Next for Obamacare? The Future of Insurance Coverage and Healthcare,” Undergraduate Interest Group in Health Policy and the Graduate Program in Health Administration and Policy, April 2017.
 - Debate moderator, “What’s Next for Health Insurance?” Chicago Booth’s 16th Annual Healthcare Conference, November 2017.
 - Invited Respondent on “Moral Failure and Health Care Costs: How the Political System Gets Health Care Wrong,” Jeffery Goldsmith, November 2017.
- Questrom School of Business
 - 2019
 - “Moral hazard and the 340B drug discount program”, Harvard-BU-MIT Health Economics Workshop, February 2019
 - Discussion moderator, “Panel: The Rising Costs of Pharmaceuticals and Value Based Care”, BU Health & Life Sciences Conference, November 2019

- IHSIP
 - 2019
 - “The Future of Drug Pricing”, The National Defense University Visit March 2019
 - “The Future of Drug Pricing”, The Inaugural IHSIP Health Policy Workshop, August 2019

A.10. Courses taught

A.10.a. The College (AB, BA, BS)

- Harvard University
 - EC 24: Health Economics, Teaching Fellow with David Cutler, Harvard College. 2 1.5-hour sections/week. Fall semester. 2002–2004.
- University of Chicago
 - BIOS 29294: Introduction to Global Health, Guest Lecturer (3 days, 1.5-hour sessions) investments in health, the financing and organization of vaccine development. S. Olopade & J. Schneider. Winter quarter. 2011, 2014, 2016.
 - PBHS 38010: Introduction to Health Economics, Course Co-director with R. Tamara Konetzka, 2 1.5-hour sections/week. Winter quarter. 2017, 2018.

A.10.b. Graduate programs (MBA, MS, MAPP, PhD)

- Harvard University
 - Teaching Fellow with Joseph Newhouse, Health Policy, Kennedy School of Government; 3 2-hour sessions/week. Spring semester. 2002.
- University of Chicago
 - CCTS 45200: Fundamentals of Health Services Research: Theory, Methods and Applications. 1–4 1.5-hour sessions/year on the Fundamentals of Health Economics, Health Reform and the Economics and Regulation of the Biopharmaceutical Industry. Summer quarter. 2007–2018.
 - PPHA 42610/CCTS 40002 Biomedical Tech: Innovation, Investment and Management, Course Director, 1 3-hour session/week. Spring quarter. 2009–2014, 2016.

- CABI 47500/CCTS 40001: Pharmacogenomics. The economics of genetic tests and treatments in Clinical Pharmacogenomics, 1 1.5-hour lecture. E. Dolan. Spring quarter. 2009–2018.
- HSTD 38400: Advanced Topics in Health Economics, Course Co-director with R. Tamara Konetzka, 2 1.5-hour sections/week. Fall quarter. 2011, 2015, 2016.
- PBHS 38010: Introduction to Health Economics. Course Co-director with R. Tamara Konetzka, 2 1.5-hour sections/week. Winter quarter. (Please note this course is also listed above). 2017, 2018.
- PPHA 42620: Biopharmaceutical Technology: Innovation, Investment & Strategy. Course director, 3 1-hour lectures/week. Spring quarter. 2018.
- Questrom School of Business
 - HM848 Driving Innovation in the Health Sector. Course director, 3 hour lectures/week. Spring semester. 2019
 - HM848 Driving Innovation in the Health Sector. Course director, 3 hour lectures/week. Spring semester. 2020
 - BA755 Describing, Analyzing, and Using Data. Course co-director, Daily lectures, three sections/week. September 2020.
 - HM848 Driving Innovation in the Health Sector. Course director, 3 hour lectures/week. Spring semester. 2021
 - BA755 Describing, Analyzing, and Using Data. Course co-director, Daily lectures, three sections/week. July-August 2021.
 - SM453 Pricing the Priceless. Course director, 2 1.5 hour lectures/week. Fall semester. 2021.
 - HM848 Driving Innovation in the Health Sector. Course director, 3 hour lectures/week. Spring semester. 2022.
 - HM717 Drugs, Devices, and Diagnostics: New Challenges, Strategies, and Execution. 3 hour lectures/week. Fall semester. 2022.

A.10.c. Graduate medical education (residency and clinical fellowships)

- CCTS 45200: Fundamentals of Health Services Research: Theory, Methods and Applications. 1–4 1.5-hour sessions/year on the Fundamentals of Health Economics,

- Health Reform and the Economics and Regulation of the Biopharmaceutical Industry. Summer quarter. (Please note this course is also listed above). 2007.
- CTSA 1: The commercialization of biomedical technologies at academic research institutions, 1.5 hour/week, Course Director, Winter quarter. 2011.

A.11. Intramural service

A.11.a. Committee membership

- University of Chicago
 - University of Chicago, Biological Sciences Division, Institutional Review Committee, Committee C, 2007–2018.
- Questrom School of Business
 - Subcommittee of HSM PDC 2018-present
 - MS biopharma leadership and innovation development committee 2018-present

A.11.b. Center and program mentorship

- University of Chicago
 - Center for Health and the Social Sciences, 2006–2018.
 - The Graduate Program on Health Administration and Policy, 2008–2018.
 - Center for Translational and Policy Research of Chronic Diseases, 2013–2018.

A.11.c. Leadership

- University of Chicago
 - Co-organizer of Health Economics Workshop, Harris School of Public Policy, September 2006–2018.
 - Pediatrics Department, Director of Health Economics residents and fellows training program (joint with Harris School of Public Policy), January 2010–2016.
 - Co-organizer of Cancer Health Economics and Policy Workshop, University of Chicago Comprehensive Cancer Center, September 2010–2017.
 - Department of Public Health Sciences, PhD Admissions Committee, Ad hoc member, 2010–2017.
 - Biological Sciences Division, Diversity and Inclusion Plan Strategy Team leader, May 2013–2016.

- Director of Public Policy and Health Economics residents and fellows training program, Pediatrics Department (joint with Harris School of Public Policy), June 2016–2017.

A.12. Grants (Selected, not comprehensive)

- Generic Cancer Drugs: Pricing and Affordability, Sponsored Program (IO) 9660304125, Sponsor Award Number RSGI-16-163-01-CPHPS, American Cancer Society, ends 12/31/2020, Award amount: 540,841.64
- Assessing Financial Difficulty in Patients with Blood Cancer, Sponsored Program (IO) 9660304125, Sponsor Award Number, Leukemia and Lymphoma Award, ends 12/31/2020, Award amount: \$800,666
- Measuring the Impact and Size of Hospital 340B Revenues, Sponsored Program (IO) 9660304125, The Commonwealth Fund, ended 5/31/2019, Award amount: 80,655.70
- Towards a new paradigm for supporting drug pricing and innovation, Sponsored Program (IO) 95503033872, Laura and John Arnold Foundation, ends 12/31/2020, Award amount: 195,528.00